CA2226759A1 - Tetracycline compounds used as cgmp specific pde inhibitors - Google Patents

Tetracycline compounds used as cgmp specific pde inhibitors Download PDF

Info

Publication number
CA2226759A1
CA2226759A1 CA002226759A CA2226759A CA2226759A1 CA 2226759 A1 CA2226759 A1 CA 2226759A1 CA 002226759 A CA002226759 A CA 002226759A CA 2226759 A CA2226759 A CA 2226759A CA 2226759 A1 CA2226759 A1 CA 2226759A1
Authority
CA
Canada
Prior art keywords
tetrahydro
pyrido
indole
dione
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002226759A
Other languages
French (fr)
Inventor
Alain Claude-Marie Daugan
Richard Frederic Labaudiniere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2226759A1 publication Critical patent/CA2226759A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

A compound of formula (I) and salts and solvates thereof, in which R0 represents hydrogen, halogen or C1-6alkyl; R1 is selected from the group consisting of: (a) hydrogen; (b) C1-6alkyl optionally substituted by one or more substituents selected from phenyl, halogen, -CO2Ra and -NRaRb; (c) C3-6cycloalkyl; (d) phenyl; and (e) a 5- or 6-membered heterocyclic ring containing at least one heteroatom selected from oxygen, nitrogen and sulphur, and being optionally substituted by one or more C1-6alkyl, and optionally linked to the nitrogen atom to which R1 is attached via C1-6alkyl; R2 is selected from the group consisting of: (f) C3-6cycloalkyl; (g) phenyl optionally substituted by one or more substituents selected from -ORa, -NRaRb, halogen, hydroxy, trifluoromethyl, cyano and nitro; (h) a 5- or 6-membered heterocyclic ring containing at least one heteroatom selected from oxygen, nitrogen and sulphur; and (i) a bicyclic ring (1) attached to the rest of the molecule via one of the benzene ring carbon atoms and A is a 5- or 6-membered heterocyclic ring as defined in point (h); and Ra and Rb independently represent hydrogen or C1-6alkyl. A compound of the present invention is a potent and selective inhibitor of cGMP specific PDE having a utility in a variety of therapeutic areas where such inhibition is beneficial.

Description

W 096J32003 PCT~P96/03023 CHE MICAL C O M PQ UN DS
.

This invention r~lates to a series of tetracyclic derivatives, to processes for their preparation, ~l~a".,aceutical cG,~,?osilior,s co"ldi"i"g them, and their use 5 as lt,erdpeutic agents. In particular, the invention relates to tetracyclic derivatives which are potent and selective i"l,iLik~r~ of cyclic guanosine 3',5'-monophosphate specific phosphodie~ clse (cGMP specific PDE) having utility in a variety of therapeutic areas where such inhibition is thought to be beneficial, including the llecl,-,enl of cardiov~scl-hr disor~Jer~.
Thus, accG~ g to a first aspect, the present invention provides compounds of forrnula (I) o R~ ~\N-R' H R O

and salts and solvates (e.g. hydrates) thereof, in which:
R~ ~ r~se,lts hy.lroge", t,~lo~eu or C1 6 alkyl;
R~ is selectecl from the group consis~li,.g of:
(a) hydrogen;
(b) C~ 6alkyl optiottally substitl~ted by one or more substituents selected from phenyl, halogen, -CO2Ra and -NRaRb;
(c) C3 6cyclocllkyl;
(d) phenyl; and (e) a 5- or 6-membered heterocyclic ring containing at least one heteroatom selected from oxygen, nitrogen and sulphur, and being optionally substituted by one or more C1 6alkyl, and optionally linked to the nitrogen atom to which R' is attached via C1~alkyl;
R2 is selected from the group consisting of:
3-6cycloalkyl;
(g) phenyl optionally substituted by one or more substituents selected from -ORa, -NRaRb, halogen, hydroxy, trifluoromethyl, cyano and nitro;

, CA 022267~9 1998-01-13 W 096/32003 PCTAEF~GI'~023 (h) a 5- or 6-men .ber~3d heterocyclic ring containing at least one h~leroalur" selected ~rom oxygen, nitrogen and sulphur; and (i) a bicyclic ring W~) ~llacl,ed to the rest of the molecl~le via one of the benzene ring carbon atoms and A is a 5- or 6-membered heterocyclic ring as defined in point (h); and Ra and Rb independently represent hydrogen or C1 6alkyl.
The term "C1 6alkyl" as used herein denotes any ~ ighl or branched alkyl chain co"l~i"i"g 1 to 6 carbon atoms, and includes methyl, ethyl, n-propyl, iso-propyl, n-butyl, pentyl, hexyl and the like.
The term "halogen" as used herein denotes fluorine, chlorine, bromine and iodine.
A particular group of col"pounds according to formula (I) are those wherein R~ represents any of hydrogen, methyl, bromine and fluorine, although of course the definition of R~ given in formula (I) inclu~es within its scope other C1 6alkyl 15 and halogen groups.
Aptly, R1 may ~presenl a suhstitl~ent selected from methyl, ethyl optionally sl~hstitlltad by one or more chlorine atoms, butyl, cyclohexyl and benzyl.
Other suit~hle R1 s~hstit~ents include hydlogel); cycloalkyl groups, such as cyclopropyl; C1 6alkyl, typically ethyl or propyl, substituted by an -NRaRb 20 substituent, such as a dimethylamino substituent; phenyl optionally linked to the nitrogen atom to which R1 is ~ che.l via a C~ 6alkyl chain, such as ethyl or thelike; and C1~alkyl, e.g. methyl, suhstitl~ted by -CO2Ra, such as -CH2CO2Et or the like.
Suitable heterocyclic rings within the cJer~"ilion of R1 include pyridyl, 25 morpholinyl, piperazinyl, pyrrolidinyl and piperidinyl. Generally such heterocyclic rings are linked to the nitrogen atom to which R1 is attached via a C~ 6alkyl chain, more appropriately a C14alkyl chain.
A par~icularly apt substituent represented by R2 is ~\0 O ~

CA 022267~9 1998-01-13 W 096/32003 PCT~EP96/03023 Other s' lit~hle R2 substituents include thienyl, pyridyl, furyl and phenyl, wherein phenyl can be sl~hstit~-ted by one or more s~hstit~ents selected from -ORa (e.g. methoxy), -NRaRb (e.g. dimethyl~",i.,o), halogen (in particular chlorine orfluorin~), hydroxy, trifluororl,~ll,yl, cyano and nitro.
Alternatively, Fl2 may represent a suitable C3 6cycloalkyl group, such as cyclohexyl or the like.
The pl.~r",ace~ltic~lly acceptaLle salts of the compounds of formula (I) which contain a basic centre are acid addition salts rorl"ed with pharm~ceutic~lly accept~L~le acids. Examples include the hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or hydrogen phospl~a~, acelale, b~3n~Gdle, succinate, fumarate, maleate, lactate, citrate, t~l l,dle, gluconate, methanesulphonate, benzenesulphona~e and p-tohlenesulphonate salts. Compounds of the formula (I) can also provicle pi.ar"laceutically acceptable metal salts, in particular alkali metal salts, with bases. Exdr"ples include the sodium and poP~si~lm salts.
It is to be understood that the pr~:senl invention covers all appropriate combinations of particular and ,~,rer~r,ed groupings hereinabove.
Particular individual compounds of the invention include:
Cis-2-benzyl-5-(3,4-methylel ,edioxyphenyl)-5,6, 1 1,11 a-tetrahydro-1 H-il, lida~o [1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-~-benzyl-5-(3,4-methylenedioxyphenyl)-5,6, 1 1,1 1 a-tetrahydro-1 H-il, lidd~o [1',5':1 ,6]pyrido[3,4-b]indole-1 ,3(2H)-dione;
Cis-5-(4-methoxyphenyl)-2-methyl-5,6,11,1 1a-tetrahydro-1 H-imidazo [1',5':1,6]
pyrido[3,4-b]indole-1 ,3(2H)-dione;
Cis-2~thyl-5-(4-rnethoxyphenyl)-5,6,11,1 1a-ltetrahydro-1 H-ill,idd~o[1~5~:1,6]
pyrido[3,4-b]indole-1 ,3(2H)-dione;
Trans-2-ethyl-5-(4-methoxyphenyl)-5,6,11,1 1a-tetrahydro-1 H-imidazo[1',5':1,6]
pyrido~3,4-b]indole-1 ,3(2H)-dione;
~ Trans-2-ethyl-5-(3,4-methylenedioxyphenyl)-5,6, 1 1,1 1 a-tetrahydro-1 H-imidazo [1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-ethyl-5-(2-thienyl)-5,6, 1 1,11 a-tetrahydro-1 H-imidazo[1',5': 1,6] pyrido [3,4-b]indole-1 ,3(2H)-dione;
Trans-5-(4-dimetloylaminophenyl)-2-ethyl-5,6, 1 1,1 1 a-tetrahydro-1 H-imidazo [1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;

CA 022267~9 1998-01-13 Trans-2-butyl-9-methyl-5-phenyl-5,6,11,1 1a-tetrahydro-1 H-ilnida~o[1',5':1,6]
pyrido[3 ,4-blindole-1 ,3(2H)-dione;
Trans-9-bromo-2-butyl-5-phenyl-5,6, 'i 1 ,1 1 a-tetrahydro-1 H-il "ida~o[1',5': 1,6]
pyrido[3 ,4-b3indole-1 ,3(2H)~ione;
Cis-2-butyl-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-i"~ida~o [1',5':1,6]
pyrido[3,4-b3indole-1 ,3(2H)-dione;
Trans-2-butyl-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-ill,idd~o [1',5':1,6]pyrido[3,4-b]indole-1 ,3(2H)-dione;
Cis-2-butyl-9-fluoro-5-(4-" ,ell ,oxyphenyl)-5,6, 11,1 1 a-tetrahydro-1 H-il, lida~o [1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-9-fluoro-5-(4-n~t:lhoxyphenyl)-5,6, 1 1 ,1 1 a-tetrahydro-1 H-il, lidd~O
[1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(3,4-methylel ~ed;oxyphenyl)-5,6 j1 1,1 1 a-tetrahydro-1 H-il "ida~o [1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-butyl-5-(3-c hlGI u,uh enyl)-5,6, 11,1 1 a-tetrahydro-1 H-imidazo[1',5': 1 ,6]pyrido [3,4-b]indole-1 ,3(2H)-dione;
Trans-2-butyl-5-(3-clllol ,phenyl)-5,6,11,1 1a-tetrahydro-1 H-i"~id~o[1',5':1,6]pyrido [3,4-b]indole-1,3(2H)-dione;
~ Cis-2-butyl-5-(4-cl,lor(),l~l,e"yl)-5,6,11,11a-tetrahydro-1H-i,.,ida~o [1',5':1,6]
pyrido [3,4-b]indole-1 ,3(2H)-dione;
Trans-2-butyl-5-(4-chlGru~ l,e"yl)-5,6,11,11a-tetrahydro-1H-i",ida~o [1',5':1,6]pyrido[3,4-b]indole-1 ,3(2H)-dione;
Trans-2-butyl-5-(4-fluorophenyl)-5,6,11,1 1a-tetrahydro-1 H-imidazo[1',5':1,6]
pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(4-hydroxyphenyl)-5,6,11,1 1a-tetrahydro-1 H-ilnida~o[1',5':1,6] pyrido [3,4-b]indole-1,3(2H)-dione;
Cis-2-butyl-5-(4-trifluGru" ,~lhylphenyl)-5,6, 1 1 ,1 1 a-tetrahydro-1 H-imidazo[1',5':1 ,6]pyrido[3,4-b]indole-1 ,3(2H)-dione;
Cis-2-butyl-5-(4-cyanophenyl)-5,6,11,1 1a-tetrahydro-1 H-imidazo[1',5':1,6] pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(4-cyanophenyl)-5,6,11,11a-tetrahydro-1H-i",ida~o[1',5':1,6]
pyrido[3 ,4-b]indûle-1 ,3(2H)-dione;
Cis-2-butyl-5-(4-nitrophenyl)-5,6, 11,1 1 a-tetrahydro-1 H-imidazo[1 ',5': 1 ,6]pyrido [3,4-b]indole-1 ,3(2H)-dione;

CA 022267~9 1998-01-13 Trans-2-butyl-5-(4-nitrophenyl)-5,6, 1 1,1 1 a-tetrahydro-1 H-il nida,o[1',5': 1,6]
pyrido[3,4-b]indole-1 ,3(2H)-dione;
Cis-2-butyl-5-(3-pyridyl)-5,6, 1 1 ,1 1 a-tetrahydro-1 H-il ~ Iidd~Oi'1 ',5':1 ,63pyrido [3,4-b]
indole-1 ,3(2H)-dione;
Cis-2-butyl-5-(3-t[lienyl)-5,6, 1 1,11 a-tetrahydro-1 H-il, lidd~o[1 ',5':1 ,6]pyrido [3,4-b]indole-1 ,3(2H)-dione;
Trans-2-butyl-5-(:3-thienyl)-5,6, 1 1 ,1 1 a-tetrahydro-1 H-imidazo[1',5': 1 ,6]pyrido[3,4-b]indole-1 ,3(2H)-dione;
Cis-2-butyl-5-(3-fllryl)-5,6, 1 1,1 1 a-tetrahydro 1 H-il "ida~o[1',5': 1 ,6]pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(:3-furyl)-5,6,11,11a-tetrahydro-1H-i,~.ida~o[1',5':1,6] pyrido[3,4-b]indole-1 ,3(2H)-dione;
Cis-2-cyolol~exyl-5-(4-methoxyphenyl)-5,6, 1 ~ ,1 1 a-tetrahydro-1 H-il~ lidd~o 11',5':1,6] pyrido[3,4-b3indole-1,3(2H)-dione;
Trans-2-cyclohexyl-5-(4-~ ll,oxyphenyl)-5,6,11,1 1a-tetrahydro-1 H-il nidd~O
[1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-cyclohexyl-9-fluoro-5-(4-- ~ ~ell ,oxyphenyl)-5,6, 1 1 ,1 1 a-tetrahydro-1 H-i..li.ld~o[1',5':1,6] pyrido[3,4-b]i"d~le 1,3(2H)-dione;
Trans-2-cyolohexyl-9-fluoro-5-(4-methoxyphenyl)-5,6,1 1,1 1 a-tetrahydro-1 H-i. . ,id~o[1~,5~: 1 ,6] pyridol3,4-b]indole-1 ,3(2H~-dione;
Trans-2-benzyl-5-phenyl-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido [3,4-b]indole-1 ,3(2H)-dione;
Cis-2-benzyl-5-(4-methoxyphenyl)-5,6,1 1 ,1 1a-tetrahydro-1 H-imidazo[1',5':1 ,6]
pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-benzyl-5-(4-methoxyphenyl)-5,6, 1 1 ,1 1 a-tetrahydro-1 H-imidazo[1',5': 1 ,6]
pyrido [3,4-b3indole-1,3(2H)-dione;
(5R,11aR)-2-benzyl-5-(3,4-methylenedioxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo [1',5':1,6]pyrido[3,4-b]indoie-1,3(2H)-dione;
Trans-2-benzyl-5-(4-hydroxyphenyl)-5,6, 11, 1 1 a-tetrahydro-1 H-imidazo [1 ',5': 1,6]
pyrido [3,4-b]indole-1 ,3(2H)-dione;
Trans-2-(2-chloroethyl)-5-(4-methoxyphenyl)-5,6, 11, 11 a-tetrahydro-1 H-imidazo[1',5':1,6] pyrido[:3,4-b]indole-1,3(2H)-dione;
Cis-2-benzyl-5-cyclohexyl-5,6,11,1 1a-tetrahydro-1 H-imidazo[1',5':1,6]
pyrido[3,4-b]indole-1 ,3(2H)-dione;

CA 022267~9 1998-01-13 Trans-2-benzyl-5-cyclohexyl-5,6, 1 1,1 1 a-tetrahydro-1 H-imidazo[1',5': 1,6]
pyridol3,4-b]indole-1 ,3(2H)-dione;
Trans-2-butyl-5-phenyl-5,6, 11, 11 a-tetrahydro-1 H-imidazo[1',5': 1 ,6lpyrido[3 ,4-b]indole-1 ,3(2H)~ione;
Trans-2-cyclohexyl-5-phenyl-5,6,11,1 1a-tetrahydro-1 H-ilnjJd~o[1~5~:1,6] pyrido[3,4-b]indole-1 ,3(2H)-dione;
Cis-2-cyclohexyl-5-phenyl-5,6, 1 1 ,1 1 a-tetrahydro-1 H-il ~ I;da~o[1',5': 1 ,6l pyrido [3,4-b]indole-1 ,3(2H)-dione;
TranS-2-ethOXY~al LGI ~ylmethyl-5-(4-methoxyphenyl)-5,6, 1 1,1 1 a-tetrahydro-1 H-imidazo[1',5':1,61 pyrido [3,4-b]i,.. la'E 1,3(2H)-dione;
Trans-5-(4-~o~ll .o~yphenyl)-2-l2-(2-pyridyl)-ethyl]-5,6, 1 1 ,1 1 a-tetrahydro-1 H-i" ,ida~o[1',5': 1 ,6]pyrido[3,4-b];. .d o l e 1 ,3(2H)-dione;
Trans-2-cycl~,n~,oyl-5-phenyl-5,6, 11, 1 1 a-tetrahydro-1 H-il ~ I;dd~0[1 ',5~ 1,6]
pyrido[3,4-b]indole-1 ,3(2H)-dione;
Trans -2-phenethyl-5-phenyl-5,6, 1 1 ,1 1 a-tetrahydro-1 H-imidazol1',5': 1 ,6]
pyrido[3 ,4-b]indole-1 ,3(2H)-dione;
Trans-5-phenyl-2-(2-pyridylmethyl)-5,6, 11,11 a-tetrahydro-1 H-il " ' [1',5':1 ,6]pyridol3,4-b]indole-1 ,3(2H)-dione;
Trans-5-phenyl-2-(~pyridylmethyl)-5,6, 11, 11 a-tetrahydro-1 H-imidazo [1',5':1 ,6]pyrido[3,4-b]ind~ I E 1,3(2H)-dione;
Trans-5-(4-methoxyphenyl)-2-(3-pyridylmethyl)-5,6, 1 1 ,1 1 a-tetrahydro-1 H-i" lid~o[1',5': 1 ,6]pyrido[3,4-b~indole-1 ,3(2H)-dione;
Trans-2-(2-di" ,~ lamino-ethyl)-5-(4-- ~ l~ll ~oxyphenyl)-5,6, 11,1 1 a-tetrahydro-1 H-i"-ida~o[1',5':1 ,6]pyrido [3,4-b]i~ 'e 1 ,3(2H)-dione;
Trans-2-(3 cli"l~ ylamino-propyl)-5-(4-~~,t ll,oxyphenyl)- 5,6,11,11a-tetrahydro -1H-imidazo[1',5':1,6] pyrido [3,4-b]i-ld~le 1,3(2H)-dione;
Trans-2-(2-morpholin4-yl-ethyl)-5-phenyl-5,6, 11,11 a-tetrahydro-1 H-imidazo[1',5':1,6~ pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-5-(4-methoxyphenyl)-2-[3-(4-methyl-piperazin-1 -yl)-propyl]- 5,6,1 1 ,1 1 a-tetrahydro-1H-imidazo[1',5':1,6~ pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-5-(4-" l~ll ,oxyphenyl)-2-(2-py, I olid;, 1-1 -yl-ethyl)-5,6, 1 1 ,1 1 a-tetrahydro-1 H-imidazo[1',5':1,6] pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-5-(4-methoxyphenyl)-2-[2-(1 -methyl-pyrrolidin-2-yl)-ethyl~-5,6, 1 1 ,1 1 a-tetrahydro -1H-imidazo[1',5':1,6~ pyrido [3,4-b]indole-1,3(2H)-dione;

CA 022267~9 1998-01-13 W 096/32003 PCT~EP96/03023 ., .

Trans-5-(4-methoxyphenyl)-5,6, 11,11 a-tetrahydro-1 H-i" lida~o[1',5': 1,6] pyrido [3,4-b]indole-1,3 (2H~-dione;
Cis-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,61 pyrido [3,4-b]indole-1,3 (2H)-dione;
~i and pl ,~" "aceutic ally acce,v~ble salts and solvates thereof.
Particularly ~r~r~:"~cl cG,~,pounds of the invention are:
(~R, 1 1 aR)-2-benzyl-5-(3,4-methylenedioxyphenyl)-5,6, 11 ,1 1 a-tetrahydro-1 H-i"lidd~O l1',5': 1 ,6]pyrido[3,4-b]indole-1 ,3(2H)-dione;
Cis-2-cyclohexyl-b-(4-methoxyphenyl)-5,6, 1 11 ,1 1 a-tetrahydro-1 H-il nidd,o [1',5':1,6] pyrido[3,4-yindole-1 ,3(2H)-dione;
Trans-2-butyl-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-i",iJd~o [1',5':1,6]
pyrido~3,4-b];"~ e 1,3(2H)-dione;
Cis-2-benzyl-5-(3,4-methylenedioxyphenyl)-~,6, 1 1,1 I a-tetrahydro-1 H-il, lida~o [1',5':1 ,6]pyridol3,4-b]indole-1 ,3(2H)-dione;
15 and pharmaceutic:ally acceptable salts and solvates thereof.

It has been shown that co"",ounds of the l,r~:senl invention are potent and selective inhibitor~ of cGMP specific PDE. Thus, compounds of forrnuia (I) are of interest for use in ll.er~y, specifically for the lr~dl",enl of a variety of 20 conditions where inhibition of cGMP specific PDE is thought to be beneficial.As a consequence of the selective PDE ~J inhibition exhibited by compounds of the present invlention, cGMP levels are elevated, which in turn can give rise to beneficial anti-plaltelet, anti-neutrophil, anti-v~cosp~slic, v~odi~tory, natriuretic and diuretic activities as well as potenlidlion of the effects of endothelium-25 derived relaxing lactor (EDRF), nitrov~so~ r:j, atrial natriuretic factor (ANF),brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and endothelium-dependent relaxing agents such as bradykinin, acetylcholine and 5-HT1. The compounds of formula (I) therefore have utility in the treatment of a ~ number of disorders, including stable, unstable and variant (Prinzmetal) angina, 30 hypertension, pulmonary hypertension, congesti~e heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e.g. post-percutaneous transluminal coronary anyioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease, illna""natory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, erectile CA 022267~9 1998-01-13 W 096/32003 P~~ Glo3o23 dysfunction and ~iseases characterised by disorders of gut motility (e.g. irritable bowel syndrome).
It will be app~ led that references herein to L~ el ll extend to prophylaxis as well as lle~lll)elll of eslab'-s'.ed condilic,.,s.
It will also be ap~,r~ 'ecl that 'a cor",~ound of formula (I),' or a physis'cyically acce~l~laL~le salt or solvate thereof can be ad~";..i;jleled as the raw compound, or as a pharmaceutical composition cor,lail);..y either entity.
There is thus provided as a further aspect of the invention a compound of formula (I) for use in the tlealll~ ll of stable, unstable and variant (P~i"~".elal) 10 angina, hypertension, pulmonary hypell~nsion, chronic obstructive pul~"ol~a"rdise~e, congestive heart failure, renal failure, all,erus~'o.~,sis, col-dilions of reduced blood vessel ,~altrl~iy, (e.g. post-PTCA), peripheral v~sull~r ~ se~se~
v~sull ~r disorders such as Raynaud's dise~se, i"nam,-ldluly ~lise~ses, stroke, bronchitis, chronic asll.l"a, ~ " gic asll.",a, allergic rhinitis, glaucoma, erectile 15 dysfunction or rlise~ses char~cl~:,ised by disorders of gut motility (e.g. IBS).
AccGr~ g to another aspect of the invention, there is provided the use of a compound of formula (I) for the manufacture of a medica",~nl for the ll~dlll,el,l of stable, unstable and variant (Prinzmetal) angina, hy~~llellsiGIl, p~.l,.,o"dr~
hypertension, chr~,l-ic obstructive pulmo"aly ~ se~se~ cG..ye~ re heart failure,renal failure, all.elosclerosis, col~d~tiG,.s of reduced blood vessel patency, (e.g.
post-PTCA), peripheral v~c~ r ~ise~se, vascular disorders such as Raynaud's disease, i"nan " "alory diseases, stroke, bronchitis, chronic asthma, allergic asll ,ma, dlleryic rhinitis, glaucoma, erectile dysfunction or ~lise~ses cha,acl~rised by disorders of gut motility (e.g. IBS).
In a further ~-spect, the invention provides a method of treating stable, unstable and variant (Prinzmetal) angina, hype~ siGn, pulmonary hypell~nsion, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, (e.g.
post-PTCA), peripheral vascular disease, vascular disorders such as Raynaud's disease, inna".malLry dise~-ses, stroke, bronchitis, chronic asthma, allergic a~ll .r"a, allergic rhinitis, glaucoma, erectile dysfunction or diseases chara~;Lerisecl by disorders of gut motility (e.g. IBS) in a human or non-human animal body which comprises admil,islering to said body a therapeutically effective amount of a compound with formula (I).

CA 022267~9 1998-01-13 W 096132003 PCT/~G~3023 Compounds olF the invention may be admi.,i~tered by any suitable route, for e~d,l"~le by oral, buccal, sub-lingual, rectal, vaginal, nasal, topical or ~arenteral (including intra~,~enous, intramusc~ r, subcutaneous and intracorc "d~ ~) lisl~dLioll. Clral admini.,l~dli~" is ye"er~lly ,.,~rt"~d.
For a.l"~ lioI~ to man in the curative or prophylactic Ll~dllllenl of the disorders identifiled above, oral ~ los,,ges of a compound of formula (I) will generally be in the range of from 0.5-800mg daily for an average adult patient (70kg~. Thus for a typical adult patient, individual tablets or capsules containfrom 0.2~00mg of active co"~,uound, in a sl~it~hlc pharmaceutically acce,~lal,levehicle or carrier~ for ad",i";.,l,dli~" in single or multiple doses, once or several times per day. Dosages for intravenous, buccal or sublingual adminislralion willtypically be within the range of from 0.1~0û mg per single dose as required. In pra~ice the physician will dete~ e the actual dosing regimen which will be most sllit~hle for an individual patient and it will vary with the age, weight and response of the particular ~dlielll. The above dosages are exemplary of the average case but there can be individual i"slances in which higher or lower dosage ranges may be r~el iled, and such are within the scope of this invention.For human use, a compound of the formula (I) can be ad",inislered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the i- ,l~n~led route of ad, ~ ~ isll dlion and standardphar")aceutical practice. For example, the compound may be admi"i~lered orally, buccally or sublingually, in the form of tablets contai"ing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture withexcipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. Such liquid ~r~pardlions may be prepared with pharmaceutically accep~d~le additives such as suspending agents (e.g.
methylcellulose, a semi-synthetic glyceride such as witepsol or mixtures of glycerides such as a mixture of apricot kernel oil and PEG-6 esters or mixtures ~ of PEG-8 and caprylic/capric glycerides). A compound may also be injected 30 parenterally, for example intravenously, intraml lscl ll~rly, subcutaneously or intracoronarily. F:or parenteral a-l,.,i"ist,~lio", the compound is best used in the form of a sterile aqueous solution which may contain other substances, for example salts, or monosaccharides such as mannitol or glucose, to make the solution isotonic with blood.

CA 022267~9 l998-0l-l3 W 096/32003 PCT~P96/03023 Thus, the invention provides in a further aspect a pharmaceutical composition comprising a compound of the formula (I) together with a pl,all"aceutically acceptable diluent or carrier ll ,erefor.
There is further provided by the prese"l invention a process of pr~pari"g a pharmaceutical co, I ~I)osi~iGn comprising a compound of formula (I), which process comprises mixing a compound of formula (I) together with a pharmaceutically acceptable diluent or carrier therefor.
A compound of formula (l~ may also be used in combination with other therapeutic agents which may be useful in the treatment of the above-mentioned ~lise~se states. The invention thus provides, in another aspect, a combination of a compound of formula (I) together with another therapeutically active agent.
The cG",bi"dlion referred to above may conveniently be presented for use in the form of a pharrnaceutic~l formulation and thus phar",aceutical composiliGns cG"~i,rising a combination as defined above together with a pharmaceutically acceptable diluent or carrier cor",~ ri~e a further aspect of the invention.
The individual cGrnponents of such a coml~illdlion may also be administered either sequentially or simultaneously in separate pharmaceutical forrnulations.
Appropriate doses of known therapeutic agents for use in combination with a compound of formula (I) will be readily appreci~ted by those skilled in the art.Compounds of formula (I) may be ,~,r~,ared by any suitable method known in the art or by the following processes which form part of the present invention. In the methods below R~, R1 and R2 are as defined in formula (I) above unless otherwise indic~ted.
Thus, a process (A) for p~t:pari,)g a compound of formula (I) comprises reacting a compound of formula (Il) o OAlk with an isocyanate of formula R1-N=C=O, in the presence of a suitable organic 30 solvent, such as a ketone solvent, e.g. butanone, acetone or the like, and under reflux for several hours e.g. 14 to 16 houm. Alk as used herein represents a C1~ialkyl group e.g. methyl.
Compounds of formula (I) may be ,),el~art:d as individual ena,~liomer~ in two steps from the a,~,urv"i~l~ e"d"li~mer ol formula (Ill) or as mixtures (e.g.
5 race",dles) of either pairs of cis or trans isomers from the co"esoondi,lg mixtures of either pairci of cis or trans iso" ,el ~ of forrnula (Ill).
Individual enantiomers of the compounds o~ the invention may be prepared from race",ates by resolution ùsing methods known in the art for the separ~lion of racemic mixtures into their co":jliluent enanlicjr"e,:i for example using HPLC
10 (high pelfi~ dlloe liquid cllru",dlu~r~l,y) on a chiral column such as Hypersil naphthylurea.
A co,.l~ound of formula (Il) may conveniently be prepared from a tryptophan derivative such as an alkyl ester thereof of formula (Ill) o Ro~OAlk (111) H
(where Alk is as previously ~ ri,led) or a salt thereof (e.g. the hydrochloride salt) according to either of the fi ~ ~;ng procedur~s (a) and (b). Procedure (b) is only suitable for preparing cis isor"er~ of formula (Ill) and may be particularly suitable 20 for preparing individual cis endl,liumer~ of formula ~Ill) from D- or L-tryptophan alkyl esters as appropriate.

Procedure (a) This comprises a Pictet-Spengler cyclisation between a compound of formula 25 (Ill) and an aldehyde R2CHO. The reaction may conveniently be effected in a ~ suitable solvent such as a halogenated hydrocarbon (e.g. dichloromethane) or an aromatic hydrocarbon (e.g. toluene) in the presence of an acid such as trifluoroacetic acid. The reaction may conveniently be carried out at a temperature of from -20~C to reflux to provide a compound of formula (Il) in one30 step. The reaction may also be carried out in a solvent such as an aromatic hydrocarbon (e.g. benzene or toluene) under reflux optionally using a Dean-Stark apparatus to trap the water produced.

CA 022267~9 1998-01-13 W 096/32003 PCTnEP96/03023 The reaction provides a mixture of cis and trans isomers which may be either individual enanliome,:j or race~ ales of pairs of cis or trans isomers dependingupon whether racemic or enantiG",erically pure tryptophan alkyl ester was used as the ~ldl lil ly "~dl~:~ ial. Individual cis or trans e"di ,liGr"ers may convenie,~lly be se~,draled from mixtures thereof by r~dctiGnal cryst~ s~lion or by chrom~luyr~,uhy (e.g. flash column chlc""alog,dphy) using appropriate solvents and eluents. Similarly pairs of cis and trans isomers may be separated by chror"atography (e.g. flash column chrumatography) using appropriate eluents.
An optically pure trans isomer may also be converted to an optically pure cis isomer using suitable epi",eri~dlion procedures. One such procedure comprises treating the trans isomer or a mixture (e.g. 1: 1 mixture) of cis and trans isomers with methanolic or aqueous hydrugen chloride at a temperature of from 0~C to the refluxing temperature of the solution. The mixture may then be subjected to chloillalo$~l~phy (e.g. flash column cl~lc",a~ography) to separate the resultingdiasl~ oisor"el~, or in the procedure utilising aqueous hydrogen chloride the desired cis isomer prer~ as out as the hydr~chlGIide salt which may then be isol~ted by filll~liGn.

Procedure (b) This comprises a four-step procedure from a compound of formula (Ill) or a salt thereof (e.g. the h~cllocl)loride salt). The procedure is particularly suitable for preparing a 1R 3R isomer of formula (Ill) from a D-tryptophan alkyl ester offommula (IV) or a salt thereof (e.g. the hydrochloride salt). Thus a first step (i) comprises treating a compound of formula (IV) with an acid halide R2COHal (where Hal is as previously defined) in the presence of a base e.g. an organic base such as a trialkylamine (for example triethylamine) to provide a compound of formula (IV) O

R~ H Alk (IV) W 096/32003 PCTAEF9''~3023 The reaction may be conveniently carried out in a suitable solvent such as a halogenated hy~dr(,c~rbon (e.g. dichloromethane) or an ether (e.g.
tetrahydrofuran) and at a temperature of from -20~C to +40~C.
Step (ii) col",u~i~es treating a co"l?ound of formula (IV) with an agent to 5 convert the amide group to a thioamide group. Suitable sulphurating agents arewell-known in the art. Thus, for example, the reaction may conveniently be effected by Ll~:dlill~ (IV) with Lawesson's reagent. This reaction may conveniently be carried out in a suitable solvent such as an ether (e.g.
dimethoxyetl-a,)e) or an ar-J",dlic hyd,ocalbon (e.g. toluene) at an elevated 10 temperature such as from 40~C to 80~C to provide a compound of formula (V) o H NHCSR 2 (\/~

Step (iii) co"".lises lleétlilly a col-,pound of formula (\/) with a suitable agent 15 to provide a col."~ound of formula ~/I) o R~ ~ Hal-(where Hal is a halogen atom, e.g. iodine). The reaction may conveniently be 20 effected by treating (Vl) with an alkylating agent such as a methyl halide (e.g.
methyl iodide) or an acylating agent such as an acetyi halide (e.g. acetyl chloride) in a suitable solvent such as a halogenated hydrocarbon (e.g dichloromethane) at an elevated temperature (e.g. under reflux).
In step (iv) the resulting iminium halide olF forrnula (\/I) may be treated with a 25 reducing agent such as boron hydride, e.g. sodium borohydride, to provide thedesired compound of formula (Il). The reduction may conveniently be effected at a low temperature, e.g. within the range of -100~C to O~C, in a suitable solvent such as an alcohol (e.g methanol) CA 022267~9 1998-01-13 According to a second process (B), a compound of formula (I) may be prepared by reaction of a compound of formula (~/II) O

R~~OAlk R (Vll) where Alk is as previously defined, with the i~ olide of R1-NH2 under suitable conditions. Compounds of formula (Vll) are known in the art and may be made by standard methods.

According to a third process (C), a compound of formula (I) where R~ represents hydrogen may be pr~:par~d by reacting a compound of formula (\/II) with urea at elevated temper~lure.

The pl Idl 11 ~ce~ ~tic~lly acceptable acid addition salts of the compounds of formula (I) which conlai-~ a basic centre may be prepared in a conventional manner. For exam,~le, a solution of the free base may be treated with a suitableacid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent.
Pharmaceutically acceptable base addition salts may be obtained in an analogous manner by treating a solution of a compound of formula (I) with a suitable base. Both types of salt may be formed or interconverted using ion-exol,al,ge resin techniques.
Compounds of the invention may be isolated in association with solvent molecules by crystallisation from or evaporation of an appropriate solvent.
Thus, according to a further aspect of the invention, we provide a process (D) for preparing a compound of formula (I) or a salt or solvate (e.g. hydrate) thereof which comprises process (A) as hereinbefore described followed by i) an interconversion step; and/or either ii) salt formation; or iii) solvate (e.g. hydrate) formation.

CA 02226759 l998-0l-l3 The synthesis of the compounds of the invention and of the il~ler"1ediates for use therein are illustrated by the following, non-limiting Examples.

Intermediates 1 and ~
Methyl 1.2.3.4-tetrahydro-1-(3.4-methylenedioxyphenyl)-9H-pyridQ[3.4-blindole-3-carboxylate. cis and trans iso",ei ~-.
To a stirred solution of racemic try~ tophan methyl ester (13 9) and piperonal (9.7 g) in anhydrous CH2CI2 ~300 mL) cooled at 0~C was added dropwise trifluoroacetic acid (9 mL) and the solution was allowed to react at ambient tel"perature. Affer 4 days, the yellow sol~tion was diluted with CH2C12 (100 mL), washed with a saturated aqueous solution of NaHCO3, then with water and dried over Na2';04. The oryallic layer was evaporal~:d to dryness under reduced pressur~ and the residue was purified by flash chromdlography eluting with CH2CI2/MeOH (99/1) to give first Intem1ediate 1. the cis isomer (6.5 9) m.p.
: 90-93~C followe~d by l-,le".ledidle ~, the trans isomer (6.4 9) m.p.: 170~C.

The following compounds were obtained in a similar "~d,.~er:

Intermediates 3 and 4 Methyl 1 ,?.3.4-tetrahydro-1-(4-methoxyphenyl)-9H-pyrido[3.4-b~indole-3-carboxylate. cis and trans isomers The same method as employed in the preparation of Interrnediates 1 and 2 but starting from racemic tny~ dn methyl ester and 4-methoxybenzaldehyde gav Intermediate 3, the cis isomer as white crystals m.p.: 142~C and Intermediate 4.2~ the trans isomer as white crystals m.p.: 209-21 0~C.

Intermediates 5 and 6 Methyl 1.2.3.4-tetrahydro-1-(2-thienyl)-9H-pyrido~3~4-b]indole-3-carboxylate, cis and trans isomer;
30 The same method as employed in the preparation of Intermediates 1 and 2 but starting from racemic try,uk"~l.an methyl ester and 2-thiophenecarboxaldehyde gave Intermediate 5, the cis isomer as a pale yellow solid m.p.: 134-1 37~C and Intermediate 6, the trans isomer as white crystals m.p. :169~C.

3~ I ntermediate 7 CA 02226759 l998-0l-l3 W 096/32003 PCT~EP96/03023 Ft~yl 1 2.3.4-tetrahydro-1 -(4-dil, lell ,ylaminophenyl)-9H-pyrido~3.4-b]indole-3-ca, boxylate. mixture of cis and trans isomer~
The same method as employed in the IJr~:pardLiGl~ of Interrnediates 1 and 2 but starting from racemic try~ to~ al) ethyl ester and 4-dimethylarllinobenzaldehyde gave the title cG,~,?ound as white crystals m.p.: 170~C.

Intermediates 8 and 9 Methyl 1.2.3.4-tetrahydro-6-fluoro-1-(4-methoxyphenyl)-9H-pyrido[3.4-blindole-3-caltJoxylate. cis and trans iso,~,er~
The same ~--~U,od as employed in the pr~par;dlion of Interrnediates 1 and 2 but sldllil-y from ~~c~r,ic 5-fluoro-tryptophan methyl ester and 4-methoxybenzaldehyde gave Inlel,-,ediate 8 the cis isomer as a solid 1H NMR
(CDCI3) ~ (ppm): 7.4~.8 (m 8H); 5.15 (brs 1H); 3.9 (dd 1H) 3.8 (s 3H); 3.2-2.9 (m 2H) and l"l~,-,.e.liate 9 the trans isomer as a solid m.p.: 197~C.
Inlen-,e.3i~les 10 and 11 Methyl 1 ~? 3 .4-tetrahydro-1 -(4-cl ,lor~ lenyl)-9H-pyridor3 .4-bpndole-3-çarboxylate. cis and trans jSGm~r~
The same ~--~ll-od as employed in the pre,l~dr~lion of Interrnedi~tes 1 and 2 but starting from racemic tryptophan methyl ester and 4-chlorobenzaldehyde gave l-,te"nediate 10. the cis isomer as white crystals m.p.: 208-209~C and Intermediate 11. the trans isomer as white crystals m.p.: 108-109~C.

Intermediates 12 and 13 Methyl 1L? 3.4-tetrahydro-1-(4-trifluoron,~lhylphenyl)-9H-pyrido~3.4-b]indole-3-carboxylate. cis and trans isori,~r:j The same method but starting from racemic tryptophan methyl ester and 4-trifluoromethylbenzaldehyde gave Intermediate 12. the cis isomer as pale yellow crystals m.p.: 190~C and Intermediate 13 the trans isomer as pale yellow crystals m.p.: 203~C.

Intermediates 14 and 15 Ethyl 1.2l3.4-tetrahydro-1-(4-cyanophenyl)-9H-pyrido~3.4-b~indole-3-carboxylate.cis and trans isomers The same method but starting from racemic tryptophan ethyl ester and 4-cyanobenzaldehyde gave l.,le",)e~lldle 14, the cis isomer as white crystals m.p.: 200~C andl Intermediate 15. the trans isomer as white crystals m.p.:
1 56~C.
Intermediates 16 and 17 F~ilyl 1.2.3.4-tetralhydro-1-(4-nitrophenyl)-9H-pyrido[3.4-b]indole-3-carboxylate.
cis and trans isomers The same ~ od but starting from rhce~ tryptophan ethyl ester and 4-nitrobenzaldehycle gave Intermediate 16, the cis isomer as yellow crystals m.p.: 168~C and lote""ediate 17, the trans isomer as yellow clystals m.p.:
1 95~C.

Intermediates 18 and 19 Ftllyl 1.2.3.4-tetralhydro-1-(3-pyridyl)-9H-pyriclo[3.4-b]indole-3-carbQxylate. cis and trans isomers The same method but slal lil ,y from , dCel ~ liC tlyptophan ethyl ester and 3-pyridinecarboxaldehyde gave Ir~l~""ediale 18, the cis isomer as pale yellow crystals m.p.: 230-232~C and Ir~le"~edi~le 19. the trans isomer as white crystals m.p.: 210-214~C.

Interrnediates 20 and 21 Fthyl 1 ~ 3,4-tetralhydro-1-(3-thienyl)-9H-pyrido[3.4-b]indole-3-carboxylate. cis and trans isomers 25 The same methocl as employed in the ,ureparaliGn of Ir,l~"ne-Ji~l~s 1 and 2 but starting from racemic tryptophan ethyl ester and 3-thiophenecarboxaldehyde gave l"ler" ,çdiate 20, the cis isomer as white crystals m.p. : 1 30~C and Intermediate 21, the trans isomer as white crystals m.p. ~182-184~C.
-30 Intermediate 22Methyl 1 ~,3.4-tetrahydro-1-(3-furyl)-9H-pyrido[3.4-b]indole-3-carboxylate.
mixture of cis and trans isomers The same method but starting from racemic tryptophan methyl ester and 3-furaldehyde gave the title compound as a yellow solid m.p : 1 30~C.

CA 022267~9 1998-01-13 W 096t32003 PCTnEP96103023 Intçrmediates 23 and 24 (1R.3R)-Methyl 1 ~ 3,4-tetrahydro-1-(3.4-methylenedioxyphenyl)-9H-pyrido[3.4-b]indole-3-ca,Loxylate. cis isomer and (1S.3R)-methyl 1 ~ 3.4-tetr~hydro-1-(3.~methylenedioxyphenyl)-9H-pyrido[3.4-b]indolç-3-ca, ~oxylate trans isomer To a stirred solution of D-tryptophan methyl ester (11 g) and piperonal (7.9 g) in anhydrous CH2CI2 (400 mL) cooled at 0~C was added dropwise trifluoroacetic acid (7.7 mL) and the solution was allowed to react at ar"bienl temperature.
After 4 days, the yellow solution was diluted with CH2CI2 (200 mL) and washed with a saturated aqueous solution of NaHCO3, then with water (3x200 mL) and dried over Na2SO4. The organic layer was evaporated under reduced pressure and the residue was purified by flash chromatography eluting with dichlGromt:ll,ane/ethyl acetate (97/3) to give first Intermediate ~-~. the cis isomer (6.5 g) m.p.: 154~C followed by l,llt:l-"ediale 24, the trans isomer (8.4 g) m.p.:
188~C.

Intermediate ~
Fthyl 1 ~.3.4-tetrahydro-6-methyl-1-phenyl-9H-pyridQ[3.4-bPndole-3-carbQxylate.
cis and trans isoll,er:~
To a stirred mixture of racemic 5-methyl-tryptophan (4 g) in 1N H2SO4 (18 mL) and water (54 mL) was added benzaldehyde (2 mL) and the solution was heated at 80~C under N2 for 48 hours.The precipitated product was collected by filtration, washed with water and dried.The crude acid (4.~ g) was then dissolved in ethanol (100 mL) and the scl ~tisn was cooled at -10~C.Thionyl chloride (1.2 mL) was added dropwise to the solution and the mixture was heated at 60~C for 48 hours.The solvent was removed under reduced pressure and the residue was taken up in ice water and basified with NH4OH.The precipited compound was washed with water, dried and purified by flash chromatography eluting with dichloromethane/methanol (98/2) to give first the cis isomer (1.7 g) m.p.: 128- ~
130~C, followed by the trans isomer (0.~3 g) m.p.: 198-200~C.

Intermediate 26 Ethyl 1.2,3.4-tetrahydro-6-bromo-1-phenyl-9H-pyrido~3.4-b]indole-3-carboxylate.
cis and trans isomers CA 02226759 l998-0l-l3 W O~'32lC~ PCTAE~9G~3023 The same procedure as described in the pr~,~drdlion of Intermediate 25 but st~ g from rac~emic 5-bromo-try~,lopl 'an and benzaldehyde gave the cis isomer as white clystals m.p.: 157-160~C and the trans isomer as white crystals m.p.: 212-216~C.

Intermediate ~7 Methyl 1 ~ 3.4-tetrahydro-1-(3-chlorophenyl)-9H-pyriclo[3.4-b~indole-3-carboxylate, mixture of cis and trans isomers 10 The same methocl as employed in the preparation of i,.l~r,nediate 1 and 2 butsta,li"g from racemic try,ulopl-a,, methyl est/_r and 3-chlorobenzaldehyde gave the title compound as white solid m.p.: 150-160~C.

Inter"~ediale 2~
Methyl 1 ~ 3.4-tetrahydro-1-(4-fluoro~henyl)-9H-~yridol3.4-b]indole-3-carboxylate. cis and trans iso",6r~
The same Ill~lllocl as employed in the ,~r~ ,dlic,l~ of intermediate 1 and 2 butstarting from racemic tryptophan methyl ester and 4-fluorobenzaldehyde gave the cis isomer as white crystals m.p.: 92~C and the trans isomer as pale yellow 20 crystals m.p. :183' C.

Intermediate 29 Methyl 1 ~ 3.4-tetrahydro-1-(4-hydroxyphenyl)-9H-pyrido[3.4-b3indole-3-carboxylate. trans isomer 25 To a stirred s~lution of ~dceri,i~ tr~lopllan methyl ester (3 g ) and 4-hydroxybenzaldehyde (1.84 9) in anhydrous dichlciru"~Ll,ane (50 mL) cooled a 0~C was added clropwise trifluoroacetic acid (1.27 mL) and the solution was allowed to react at ambient temperature. A~ter 22 hours the solution was - washed with a saturated solution of NaHCO3. then with water dried over30 Na2SO4 and evaporated to dryness. The residue was purified by flash ch~ulllaLuy,~,~hy eluting with ethyl acet~le to give the title compound (3.48 9) as an off-white solid m.p.: 233-235~C.

Example 1 W O 96/32003 PCTA~P96/03023 Cis-7-benzyl-5-(3,4-methylenedioxyphenyl)-5.6. 1 1 .1 1 a-tetrahydro-1 H-imidazo[1'.5':1.6]nyrido[3.4-b]indole-1,3~?1 I)-dione and Trans-~-ben~yl-5-(3.4-methylenedioxyphenyl)-5.6,11.1 1a-tetrahydro-1 H-ill ! iZi,.-) [1'.5':1.63Dyrido[3.~blindQle-1.3~?1 J)~ione To a stirred sol ltion of a mixture of cis and trans isomers of Inle"nerli~tes 1and 2 (19, 2.85 mmol) in 2-butanone (50 mL) was added dropwise benzyl isocyanate (0.37 mL, 2.99 mmol) and the mixture was refluxed for 15 hours. The solvent was then removed under reduced pressure and the residue was purified by flash chlc,,,dluyra~hy eluting with toluene/ethyl acetate: 85115 to give first, 10 the trans iso",er (240 mg) as white crystals after recry~ lion from diethyl ether. m.p.: 208-210~C.
Analysis for C27H2~N3O4:
C~lu~hte~: C,71.83;H,4.69;N,9.31;
Found:C,71 .46;H,4.77;N,9.24%.
and followed by the cis isomer (470 mg) as white crystals after recryst~llis~tion from elha,)ol. m.p.: 159-161~C.
Analysis for C27H2'N3O4:
G~lcl~l~ted: C,71.83;H,4.69;N,9.31;
Found:C,71.79;H,4.80;N,9.09%.

FY~mple 2 (;:is-5-(4-methoxyphenyl)-2-methyl-5.6. 1 1 .11 a-tetrahydro-1 H-imidazo [1'.5':1 .6]
pyrido[3 .4-b]indole-1 .3~ -dione The same method as employed in the preparation of Example 1 but slalLillg from Illte,l"ediate 3 and methyl isocyanate gave after recryst~ilisation from ethanol, the title compound as white crystals m.p.: 233-240~C.
Analysis for C21H1gN3O3 Calculated: C,69.79;H,5.30;N,11.63;
Found:C,69.63;H,5.29;N,11.68%.

F~(ample 3 Cis-2-ethyl-5-(4-methoxyphenyl)-5.6.11.11a-tetrahydro-1H-imidazo[1'.5':1.6]
pyrido~3.4-b]indole-1.3(2H)-dione and CA 02226759 l998-0l-l3 W 096/32003 PCT~P96/03023 Trans-~-ethyl-5-(4-methoxyphenyl)-5.6. 1 1.1 1 a-tetrahydro-1 H-imidazo[1'.5': 1.6]
~yrido[3.4-b]indole-1.3~71 I)-dione The same method as employed in the pre~ar~lio" of Example 1 but ~ li"g from a mixture of l"l~:r",e~ les 3 and 4 and ethyl isocyanate gave the cis isomer as white crystals after recrystallisation from elllP n ol m.p.: 210-220~C.
Analysis for C22H2,N3O3:
Calculated: C,70.38;H,5.64;N,11.19;
Found:C,69.97;H ,5.71 ;N, 10.83%.

and the trans isomer as white crystals after recryst~llis~lio" from 2-propanol m.p.: 245-248~C~
Analysis for C22H2,N3O3:
Calculated: C,70.38;H,5.64;N,11.19;
Found:C,70.28;H,5.76;N,1 1.22%.
F~rnple 4 Trans-'~-ethyl-5-(3.4-methylenedioxyphenyl)-5.6. 1 1 .1 1 a-tetrahydro-1 H-imida~o [1',5':1.6]Dyrido[3,4-b]indole-1.3~?1 I)-dione The same ~ ll-od as employed in the ,v~ ardlion of Example 1 but starting from the Intermediate 2 and ethyl isocyanate gave after recryst~llis~lio" from ethyl acelal~/hexane, the title compound as white crystals m.p.: 238~C.
Analysis for C22H19N3O4:
C~lc~ ~d: C,67.86;H,4.92;N,10.79;
Found:C,68.32;H,4.90;N,10.90%.
F~mple 5 Trans-2-ethyl-5-(2-thienyl)-5.6. 1 1 .1 1 a-tetrahydro-1 H -imidazo[1'.5': 1 .6] pyrido [3 4-b]indole-1.3(2H)-dione - The same melhod as employed in the preparation of Example 1 but starting 30 from ll~tel-,lediate 6 and ethyl isocyanate gave after recryst~llis~tion from2-propanol, the title compound as white crystals m.p.: 242-248~C.
Analysis for C19H,7N3O2S:
Calculated: C,64.94;H,4.88;N,11.96;
Found:C,64.79;H,5.00;N,1 1.88%.

Example 6 Trans-5-(4~il ~ ~ll Iylaminophenyl)-~-ethyl-5.6. 11 .1 1 a-tetrahydro-1 H-imid:~7n [1'.5':1.6] pyrido~3.4-b]indole-1.3~71 I)~ione The same ~ lllod as employed in the ,ur~.ar~liol) of Exa~ ,le 1 but stallin~
5 from a mixture of cis and trans ison,er~ of Inl~r".edi~ 7 and ethyl isocyanategave after recrys~ liol~ from ,..ell,a"ol, the title compound as white crystals m.p.: 262-265~C.
Analysis for C23H24N4O2:
C~lc~ ted: C,71.11 ;H,6.23;N,14.42;
Found:C,71.01 ;H,6.29;N,14.49%.

Fxample 7 Trans-7-buty1-9-methyl-5-phenyl-5.6.11.1 1a-tetrahydro-1 H-ilnidd~o~1~.5~:1.6]
pyrido[3.4-b]indole-1,3C?l I)~ione The same l"etl.ocl as employed in the preparation of Example 1 but starting from the trans isomer of Inl~"nediala 25 and butyl isocyanate gave after recryst~ szllioll from diisopropyl ether, the title compound as white crystals m.p.
: 196-198~C.
Analysis for C24H25N3O2:
Calcul~t~d: C,74.39;H,6.50;N,10.84;
Found:C,74.38;H,6.52;N,1 0.63%.

F~ample 8 Trans-9-bromo-?-bub~1-5-phenyl-5.6.11.11a-tetrahydro-1H-imi~ 1'.5':1.6]
pyrido[3.4-b];.. -3cl~ 1.3~?1 I)~ione The same ,nell.od as employed in the preparation of Example 1 but starting from the trans isomer of Interrnediate 26 and butyl isocyanate gave after recrystallisation from diisopropyl ether, the title compound as white crystals m.p.
: 207-210~C.
Analysis for C23H22BrN3O2:
G~lcul~ted C,61.07;H,4.90;Br,17.66;N,9.29;
Found:C,61 .28;H,4.95;Br, 1 7.53;N,9. 10%.

Example 9 W 096/32003 PCTnEP96/03023 Cis-2-butyl-5-(4-methoxyphenyl)-5.6. 1 1 .1 1 a-tetrahydro-1 H-imidazo [1'.5':1.6]
pyrido[3.4-b]indole-1.3~?1 I)-dione The same In~ od as employed in the preparation of Example 1 but starting from the l.,l~,--.eclidle 3 and butyl isocyanate gave after recryst~ lio,~ from ,neU,dllol~ the title cGnl,)ound as white crystals m.p.: 220-225~C.
Analysis for C24H2~N3O3:
Calcul~te~l: C,71.44;H,6.25;N,10.41;
Found:C,71 .56;H,b.23;N,10.36%.

FY~rnple 10 Trans-~-butyl-5-(4-methoxyphenyl)-5.6. 11. 1 1 a-tetrahydro-1 H-i~ "ida~o ~1 '.5': 1.6]
pyrido[3 .4-b]indole-1 .3(2H)-dione The same loell-od as employed in the preparation of Example 1 but ~Idllin~
from the l~ ""ecliate 4 and butyl isocyanate gave after recrystallisation from ethanol/water, the title compound as white crystals m.p.: 173-174~C.
Analysis for C24H25N3O3:
Calc~ t~rl: C,71.44;H,6.25;N,10.41;
Found:C,7 1.53; H ,6.20;N ,10.28% .

F~cample 11 Cis-2-butyl-9-fluoro-5-(4-methoxyphenyl)-5.6. 1 1.1 1 a-tetrahydro-1 H-imidazo [1'.5':1.6] pyrido[3~4-b~indole-1.3(2H)-dione The same method as employed in the pl~.ardlio-, of Example 1 but starting from Intermediate 8 and butyl isocyanate gave after recryst~ lion from methanol,thetitlec~ oundaswhitecrystals m.p.: 125-130~C.
Analysis for C24H24FN3O3 (0.3H2O):
Calculated: C,67.53;H,5.81;N,9.84;
Found:C,67. 1 9;H,5.74,N,9.85%.

Example 12 Trans-2-butyl-9-fluoro-5-(4-methoxyphenyl)-5.6.1 1 .1 1 a-tetrahydro-1 H-imidazo[1'.5':1.6~ pyrido~3.4-b~indole-1.3(2H)-dione The same method as employed in the preparation of Example 1 but starting from the Intermediate 9 and butyl isocyanate gave after recrystallisation from W 096/32003 PCT~EP96/03023 diisopropyl ether/pentane, the title compound as white crystals m.p.: 187-1 89~C.
Analysis for C24H24FN3O3:
Calc~ t.~d: C,68.39;H,5.74;N,9.97;
Found:C,68.61 ;H,5.71 ;N,10.04%.

Fxample 13 Trans-2-butyl-5-(3.4-methylenedioxy~henyl)-5.6. 1 1.1 1 a-tetrahydro-1 H-imid~n [1',5':1.6] ~yrido[3,4-bpndole-1.3~?1 I)-dione The same method as employed in the pr~ ,dlio" of Example 1 but ~lallil)g from Intermediate 2 and butyl isocyanate gave after recrystallisation from 2-propanol, the title cor.,?ound as white crystals m.p. :152~C.
Analysis for C24H23N3O4:
C~lclll~ted: C,69.05;H,5.55;N,10.07;
1 5 Found:C,68.93;H,5.49;N,9.99%.

F~mple 14 Cis-?-buty1-5-(3-cl ,lor~l ,enyl)-5.6. 1 1 .1 1 a-tetrahydro-1 H-imidazol1'.5': 1 .6]Dyrido [3.4-b]indole-1.3~ )-dione and Trans-2-butyl-5-(3-chlor~ ellyl)-5.6.11.11a-tetrahydro-1H-imidazo[1'.5':1.6]
pyrido [3.4-b]indole-1.3~2H)-dione The same method as employed in the preparation of Example 1 but starting from a mixture of cis and trans ison.er~ of ll,le""e-liate 27 and butyl isocyanate gave the cis iso",er as pale yellow crystals after recryst~ s~lion from diethyl ether/cyclGht:xal.e m.p.: 215-217~C.
Analysis for C23H22ClN3O2:
Calculated: C,67.73;H,5.44;CI,8.69;N,10.30;
Found:C,67.62;H,5.49;CI,8.59;N,10.03%.

and the trans isomer as white crystals after recrystallisation from ethanol m.p.:
207-209~C.
Analysis for C23H22ClN3O2:
Calculated: C,67.73;H,5.44;CI,8.69;N,10.30;
Found-C,67.60;H,5.41 ;CI,8.77;N,1 0.20%.

.
W 096/32003 PCTnE~9C~'~3023 FY~rnple 15 Cis-7-butyl-5-(4-chlorophenyl)-5.6.11.11a-telrahydro-1H-imidazo [1'.S':1.6]
pyrido [3.4-b]indole-1.3~N)-dione The same Illetllo~ as employed in the preparation of Example i but starting 5 from It~ e-l;ate 10 and butyl isocyanate gave after recryst~llis:ltion from methanol, the title compound as pale yellow crystals m.p.: 252~C.
Analysis for C23H22ClN3O2:
Calclll~te~l: C,67.'73;H,5.44;CI,8.69;N,10.30;
Found:C,67.60;HJ5.44;CI,8.55;N, 1 0.30%.
F~ample 16 Trans-2-butyl-5-(4-chlorophenyl)-5.6.11.11 a ~tetrahydro-1 H-i",i.l~o [1'.5':1.6pyridol3.4-b3indole-1 .3C?H)-dione The same method as employed in the preparation of Example 1 but starting 15 from l~ ",~ediale 11 and butyl isocyanate gave after recrystallisation from methanol, the title cGmpound as pale yellow crystals m.p.: 174~C.
Analysis for C23H22CIN3O2:
Calculated: C,67.73;H,5.44;CI,8.69;N,10.30;
Found:C,67.75;H,5.49;CI,8.75;N,1 0.46.%
E~xample 17 Trans-2-butyl-5-(4-fluorophenyl)-5.6. 11 .1 1 a-tetrahydro-1 H-imidazo[1'.5': 1 .6]
pyrido [3.4-b3indole-1.3~?H)-dione The same rllelhod as employed in the ,~reparalion of Example 1 but starting 25 from the trans isomer of ll~,eclidle 28 and butyl isocyanate gave after recrystallh~lio,~ fiom 2-propanol, the title compound as pale yellow crystals m.p.
: 242~C.
Analysis for C23H22FN3O2:
- Calculated: C,70.57;H,5.66;F,4.85;N,10.73;
Found:C,70.57;H,5.63;F,4.66;N,10.83%.

~xample 18 Trans-2-butyl-5-(4-hydroxyphenyl)-5.6.11.1 1a-tetrahydro-1 H-imidazo[1'.5':1.6]
pyrido [3.4-b]indole-1.3(2H)-dione The same method as employed in the preparation of Example 1 but starting from Inl~:r."el~iate 29 and butyl isocyanate gave after recryst~ s~tion from 2-propanol/water, the title compound ~s white crystals m.p.: 259~C.
Analysis for C23H23N3O3:
C~lc~ te~: C,70.93;H,~.95;N,10.79;
Found:C,70.41 ;H,6.04;N, 10.63%.

Fxample 19 (::is-2-butyl-5-(4-trifluoromethylphenyl)-5.6. 1 1 .1 1 a-tetrahydro-1 H-i~ ,n 11'.5':1 .6]Dyrido[3.4-b]i~ Idol~ 1 .3(2H) ciione The same method as employed in the preparation of Example 1 but starting from l"l~:lmediate 12 and butyl isocyanate gave after recryst~ s~tion from methanol/water, the title co",,l~ound as pale yellow crystals m.p.: 232~C.
Analysis for C24H22F3N3O2:
Calc~ ted: C,65.30;H,5.02;F,12.91;N,9.52;
Found:C,6~.29;H,5.05;F,12.56;N,9.37%.

F~:~mple ?0 Cis-7-butyl-5-(4-cyanophenyl)-5.6.11.11a-tetrahydro-1H-imi-l~7~1'.5':1.6] pyrido[3~4-b]indole-1~3(2H)-dione The same method as used in the preparation of Example 1 but starting from Intermediate 14 and butyl isocyanate gave after recrystallisation from 2-propanol, the title compound as white crystals m.p.: 260~C.
Analysis for C24H22N4O2:
C~lcl~lated: C,72.34;H,5.57;N,14.06;
Found:C,72.30;H,5.59;N,14.08%.

Example 21 Trans-2-butyl-5-(4-cyanophenyl)-5.6. 11 .1 1 a-tetrahydro-1 H-imidazo[1'.5': 1 .6]
pyrido[3.4-bpndole-1.3(2H)-dione The same method as employed in the pr~pardlion of Example 1 but starting from Intermediate 15 and butyl isocyanate gave after recrystallisation from diethyl ether/cyclohexane, the title compound as white crystals m.p : 1 58~C.
Analysis for C24H22N4O2:

C~lcul~ted: C,72.34;H,5.57;N,14.06;
Found:C,72.40;H,5.56;N, 1 3.95%.

FY~mple ~
Cis-2-butyl-5-(4-nitrophenyl)-5.6. 1 1.11 a-tetrahydro-1 H-i" ,idd~o[1'.5': 1 .6]pyrido [3.4-b]indole-1.3(2H)-dione and Trans-2-butyl-5-(4-nitrophenyl)-5.6. 11 ,1 1 a-tetrahydro-1 H-imidazo~1'.5': 1.6]
pyrido[3 .4-b]indole-1 .3(2H)-dione The same method as employed in the preparation of Example 1 but starting from a mixture of Interme~ tes 16 and 17 and butyl isocyanate gave the cis isomer as yellow crystals after recryst~ liGI~ from mell ,anol m.p.: 236~C.
Analysis for C23H22N4O4:
C~lc~ ted: C,66.02;H,5.30;N,13.39;
Found:C,65.82;H,!;.36;N, 1 3.26%.
and the trans isomer as yellow crystals after recrystallis~tion from 2-propanol m.p.: 206~C.
Analysis for C23H2~N4O4:
G~lclJIat?cl: C,66.02;H,5.30;N,13.39;
Found:C,66. 1 2;H,5.38;N, 13.28%.

Example 2~
Cis-2-butyl-5-(3-pyridyl)-5.6. 1 1 .1 1 a-tetrahydro-1 H-imida~o[1'.5': 1 .6]pyrido ~3.4-b]
indole-1 .3(2H)-dione The same method as employed in the p~ drdlioll of Example 1 but starting from Intermediate 18 and butyl isocyanate gave after recrystallisation from 2-propanol, the title compound as white c~stals m.p.: 257-263~C.
Analysis for C22H22N4O2:
- Calculated: C,70.57;H,5.92;N,14.96;
Found:C,70.38;H,6.07;N,14.88%.

Example 24 Cis-2-butyl-5-(3-thienyl)-5.6. 1 1 .1 1 a-tetrahydro-1 H-imidazo[1'.5': 1 .6]pyrido ~.4-b]indole-1.3(2H)-dione and Trans-2-butyl-5-(3-thienyl)-5.6.1 1 .1 1 a-tetrahydro-1 H-imidazo[1'.5': 1 .6]
pyrido[3,4-bpndole-1.3~?1 I)-dione The same n)~U-od as employed in the ,t)r~ rdlio" of Example 1 but sldllilly from a mixture of l..k:,...ecl;-l.es 20 and 21 and butyl isocyanate gave the cisisomer as white crystals after recryst~ ,.lio" from 2-~rupanol m.p.: 219-221~C.
Analysis for C2~H2~N3O2S:
Calculated: C,66.47;H,5.58;N,11.07;S,8.45;
Found:C,66. 1 3;H,5.68;N, 1 1 .OO;S,8.27%.

and the trans isomer as white cr,vstals after recry~l;.ll;s~lion from ethyl acetate m.p.: 240-242~C.
Analysis for C2,H2~N3O2S:
Calclll~te~l: C,66.47;H,5.58;N,11.07;S,8.45;
Found:C,66.68;H,5.69;N,1 1.05;S,8.56%.
FY~ple ~
Cis-7-buty1-5-(3-fury1)-5.6. 11. 1 1 a-tetrahydro-1 H-il I li~a~o[1 '.5': 1 .6~pyrido [3.4-b]indole-1.3~ dione and Trans-?-bubr1-5-(3-fur,vl)-5.6. 11. 1 1 a-tetrahydro-1 H-il "i. I, ~1 '.5': 1.6] pyrido~3.4-b]indole-1.3~ )-dione The same ..-~:ll.od but slallilly from a mixture of cis and trans isomers Intermediate 22 and butyl isocyanate gave the cis isomer as white crystals afterrecrystallisation from toluene m.p.: 155-160~C.
Analysis for C2,H21N3O3:
Calcul~ted: C,69.41;H,5.82;N,11.56;
Found:C,69.44;H,5.86;N,1 1 .52%.

and the trans isomer as pale yellow crystals after recrystailisation from ethanol m.p.: 215-219~C.
Analysis for C2~H2~N3O3:
C~lc~ te~: C,69.41 ;H,5.82;N,11.56;
Found:C,69.43;H,5.73;N,1 1 .46%.

Example 26 W 096132003 PCT~P96/03023 Cis-2-cyclohexyl-5-(4-methoxyphenyl)-5.6. 1 1 .1 1 a-tetrahydro-1 H-il, lidd~o [1'.5'-1.6] pyridol3.4-b]indole-1.3(2H)-dione and Trans-2-cyclohexyl-5-(4-methoxyphenyl)-5.6.11.11a-tetrahydro-1H-i [1'.5':1.6] ~yrido[3,4-b]indole-1.3(~1 I)-dione The same method as employed in the preparation of Exa"~ple 1 but ~tallilly from a mixture of Intermedi~les 3 and 4 and cyclohexyl isocyanate gave the cis isomer as white crystals after recrystallisation from ethanol m.p.: 250-260~C
Analysis for C26H27N3O3:
~lc~llate~: C,72.71;H,6.34;N,9.78;
Found:C,72.73;H,6.39;N,9.63%.

and the trans isomer ~s white crystals aFter recryst~i ~zllion from 2-propanol m.p.: 265-269~C.
Analysis for C26H27N3O3:
C~lcl ~l~te~: C,72.71 ;H,6.34;N,9.78;
Found:C,72.82;H,6.38;N,9.69%.

Fxaml?le 27 Cis-7-cyclol ,exyl-SI-fluoro-5-(4-, n~ll ,oxyphenyl)-5.6.1 1.1 1 a-tetrahydro-1 H-i.ni~ 1'.5':1.63 pyrido[3.4-b]i"~l~le 1.3C~H)-dione The same method as employed in the p,~ p~rdliGn of Example 1 but starting from Intermediate 8 and cyclohexyl isocyanate gave after recrystallisation from m ~ll .al ,ol, the title compound as white crystals m.p.: 275-278~C.
Analysis for C26H26FN3O3:
C~lc~ te~l: C,69.~78;H,5.86;N,9.39;
Found:C,69.75;H,5.85;N,8.96%.

Example 28 Trans-2-cyclohexyl-9-fluoro-5-(4-methoxyphenyl)-5.6. 11.1 1 a-tetrahydro-1 H-imidazo[1'.5':1.6~ pyrido[3.4-b]indole-1.3(2H)-dione The same method as employed in the pl~.ardlioil of Example 1 but starting from Intermediate 9 and cyclohexyl isocyanate gave after recrystallisation from ethanol, the title compound as white crystals m.p.: 265-267~C.
Analysis for C26H26FN3O3:
Calculated: C,69.78;H,5.86;N,9.39;

W 096/32003 PCT~EP96/03023 Found:C,69.71 ;H,5.91 ;N,9.37%.

FY~rnple ~
Trans-2-ben7yl-5-phenyl-5.6,1 1 .1 1 a-tetrahydro-1 H-imirl~ [1'.5':1 .6]pyrido 13.4-5 b1indole-1.3(2H)-dione The same l-,etl-od as employed in the pr~uar~lio,, of l=xample 1 but ~ldllillg from trans methyl 1,2,3,4-tetrahydro-1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylate~ and benzyl isocyanate gave after recrystallisation from diethyl ether, the title compound as white crystals m.p.: 200-202~C.
Analysis for C26H21N3O2:
C~lc~ ted C,76.64;H,5.19;N,10.31;
Found:C,76.75;H,5.1 8;N,1 0.23%.
1. Cook J., Sandrin J. and Soerens D., Heterocycles, 4, no. 7, 1249 - 1255 (1 976).
F~ ple 3Q
Cis-7-ben~y1-5-(4-metho)~yphenyl)-5,6.11.1 1a-tetrahydro-1H-imirl~7n~1'.5':1 .6]pyrido [3.4-b~indole-1.31?1 I)-dione The same method as employed in the pr~.ardlio" of Example 1 but sla~ g 20 from Interrnediate 3 and benzyl isocyanate gave after recryst~ lion from ethanol, the title compound as pale yellow crystals m.p.: 240-243~C.
Analysis for C27H23N3O3:
Calcul~te~l: C,74.13;H,5.30;N,9.60;
Found:C,74.13;H,5.31 ;N,9.58%.
2~
F~rnple 31 Trans-2-be~7yl-5-(4-methoxyphenyl)-5.6.11.11a-tetrahydro-1H-imidazo[1'.5':1.6]
pyrido ~3.4-b~indole-1.3(2H)-dione The same method as employed in the preparation of Example 1 but starting 30 from Intermediate 4 and benzyl isocyanate gave after recrystallisation from 2-propanol, the title compound as white crystals m.p.: 208-Z12~C.
Analysis for C2,H23N3O3:
Calculated: C,74.13;H,5.30;N,9.60;
Found:C,74.25;H,5.47;N,9.49%.
3~

w 096/32003 PCTAEP96/03023 Example 32 (5R.11 aR)-2-~enzyl-5-(3.4-methylenedioxyphenyl)-5.6.11.11 a-tetrahydro-1 H-i",~ [1'.5':1.6~nyrido[3~4-b~indole-1 3~71 I)~ione The same ,.~ell,od as employed in the pr~ ar~liol1 of Exa,..ple 1 but starting from Inl~llnediate 23 and benzyl isocyanate, gave aKer recrystallis~lion toluene, the title compouncl as white crystals m.p.: 145~C.
Analysis for C27H21N3O4:
C~IG~IIateCI: C,71.83;H,4.69;N,9.31;
Found:C,71.47;H,4.74;N,9.28%.
FY;tm~le 33 Trans-2-ben7yl-5-~4-hydroxyphenyl)-5.6.11.11 a-tetrahydro-1 H-imida~o 11 '.5': 1.6]
pyrido [3.4-b]indole-1,3~H)-dione The same .l~ell.~d as employed in the prt,p~r;dlion o~ Example 1 but starting from Interrnediate 29 and benzyl isocyanal:e gave after recrystallis~lio~ from methanol, the title co"l~ound as white crystals m.p.: 268-272~C.
Analysis for C26H2,N3O3:
Calc-ll~te~l: C,73.74;H,5.00;N,9.92;
Found:C,73.63;H,!5.09;N,10.02%.
Example 34 Trans-2-(2-chloroethyl)-5-(4-methoxyphenyl)-5.6.11.11 a-tetrahydro-1 H-imidazo [1'.5':1.6] pyrido~3,4-b]indole-1.3~ ) clione The same method as employed in the ,~r~pardlion of Example 1 but starting from Intermediate 4 and 2-chloroethyl isocyanate, gave after recrystallis~lioo from diethyl ethel/l-e~re, the title compound as white crystals m.p.: 218-219~C.
Analysis for C22H20CIN3O3:
Caiculated: C,64.47;H,4.92;C1,8.65;N,10.25;
Found:C,64.44;H,-4.98;CI,8.81;N,10.20%.
Example 35 Cis-2-benzyl-5-cyclohexyl-5,6.11.11a-tetrahydro-1 H-imidazo[1',5':1.6]
pyrido[3.4-b]indole-1.3(2H)-dione The same method as employed in the preparation of Example 1 but starting from cis methyl 1,2,3,4-tetrahydro-1-cyclohexyl-9H-pyrido[3,4-b]indole-3-W 096/32003 PCT~EP96/03023 carboxylate1 and benzyl isocyanate gave after recryst~ s~tion from methanol, the title compound as white crystals m.p.: 170-173~C.
Analysis for C26H27N302:
C~lc~ t~rl: C,75.52;H,6.58;N,10.16;
Found:C,75.63;H,6.48;N,9.75%.
1 . Cook J., Sandrin ~1. and Soerens D., Heterocycles, _, no 7, 1249-1255 (1976).
Fxample 36 Trans-~-benzyl-5-cyclohexyl-5.6,11,11a-tetrahydro-1H-i",i~la~o~1'.5':1.6]
pyrido[3.4-b~indole-1.3~?H)-dione The same method as employed in the pr~a.dlio" of Exa,.~le 1 but starting from trans methyl 1,2,3,4-tetrahydro-1-cyclol.exyl-9H-pyrido[3,4-b]i..~l~l 3-carboxylate~ and benzyl isocyanate gave after recry~ s~lion from methanol, the title compound as white crystals m.p.: 130-135~C.
Analysis for C26H27N302:
C~lc~ t~ C,75.52;H,6.58;N,10.16;
Found:C,75.74;H,6.67;N,9.94%.
1 . Cook J., Sandrin J. and Soerens D., Heterocycles, 4, no 7, 1249-1255 (1976).
Fxample 37 Trans-7-buty1-5-phenyl-5.6.11.11 a-tetrahydro-1 H-i~ 1 '.5': 1.63pyrido~3.4-b]indole-1.3~71 I)-dione The same method as employed in the pr~pa.dlion of Exd,n,~l~ 1 but starting from trans methyl 1,2,3,4-tetrahydro-1-phenyl-9H-pyrido[3,4-b~indole-3-carboxylate and butyl isocyanate gave after recryst~ s~tion from 2-propanol, the title compound as white crystals m.p.: 240-243~C.
Analysis for C23H23N302:
C~lcl ~l~tesl: C,73.97;H,6.21 ;N,11.25;
Found:C,73.95;H,6.32;N,11.28%.
F~mple 38 Trans-2-cyclohexyl-5-phenyl-5.6.11.11 a-tetrahydro-1 H-imidazo~1 '.5': 1.6] pyrido ~3,4-b]indole-1.3(2H)-dione The same method as employed in the preparation of Example 1 but starting from trans methyl 1,2,3,4-tetrahydro-1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylate and cyclohexyl isocyanate gave after recrystallisation from methanol, the title compound as white crystals m.p.: 248-250~C.
Analysis for C25H25N302:
Calculated: C,75.16;H,6.31 ;N,10.52;
Found:C,75.23;H,6.33;N,10.60%.

W 096/32003 PCT~EP96/03023 Example 39 Cis-2-cyclohexyl-5-phenyl-5.6.11.11 a-tetrahydro-1 H-imidazo[1 '.5'~ pyrido [3.4-b]indole-1.3~?11) clione The same method as employed in the pr~3p~rdliG" of Example 1 but sl~,li.,g from cis methyl 1,2,3,4-tetrahydro-1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylateand cyclohexyl isocyanate gave after recry:,lall.sdliol) from methanol, the title compound as white crystals m.p.: 267-270~C.
Analysis for C2~H25N302:
C~lcul~tRd: C,75.16;H,6.31;N,10.52;
Found:C,75.20;H,6.33;N,10.52%.
FY~rnple 40 Trans-7-ethoxycarbonylmethyl-5-(4-methoxyphenyl)-5.6.11.11 a-tetrahydro-1 H-1'.5':1.6] ~yrido [3.4-b]i.l~olc~ 1.3~ clione The same ~ tllod as employed in the p~ liGn of Example 1 but starting from Intermediate 4 and ethyl isocy;~.,a~o:~cet~te gave after recrystallisation from ethanol, the title cu,,-pound as white crystals m.p.: 165-167~C.
Analysis for C24H23N305:
Calculated: C,66.'iO;H,5.35;N,9.69;
~0 Found:C,66.66;H,5.32;N,9.66%.
F~rnple 41 Trans-5-(4-methoxyphenyl)-~-[2-~?-pyridyl)~thyl]-5.6.11.11 a-tetrahydro-1 H-i" .i~ 1 ',5': 1.6lnyrido[3.4-b]i- ,J~ le 1.3(~H)~ione To a stirred solution of c~,~onyl diimidazole (0.28 g, 1.72 mmol) in dry tetrahydrofuran ~5 mL), was added d~up~.~i.,c a solution of 2-(2-aminoethyl)pyridine (0.205 9, 1.68 mmol) in tetrahydrofuran (3 mL) and the solution was stirred at room temperature For 0.5 hour. Then, a solution of Intermediate 4 (0.~5 9, 1.43 mmol) in dly tetrahydrofuran (7 mL) was added and 30 the resulting solution was refl~xed for 20 hours. The solvant was removed under reduced pressure and the residue was dissolved in dichloru,,,eU,a,.e (50 mL).
The solution was washed three times with water (3x20 mL), dried over Na2S04 and conce--tl~l~d. The residue was then purified by flash chromatography eluting with dichloromethane/methanol: 9911 and recrystallised from ethanol/water to give the title compound (0.35 9) as white crystals m.p.: 140-143~C.
Analysis for C27H24N403:
C~lcui~ted: C,71.67;H,5.35;N,12.38;
Found:C,71.87;H,5.41 ;N,12.28%.
Example 42 Trans-2-cyclopropyl-5-phenyl-5.6.11.11 a-tetrahydro-1 H-imidazo[1 '.5':1.6]
pyrido[3.4-b]indole-1.3(2H)-dione - =

The same method as employed in the p,~ rdlion of Example 41 but starting from trans methyl 1,2,3,4-tetrahydro-1-phenyl-9H-pyrido[3,4-blindole-3-carboxylate and cyclo~ropylamine gave after recrystallisation from ethanol, the title CGI ,Ipound as white crystals m.p.: 250-255~C.
Analysis for C22H19N302:
C~lclll~te~: C,73.93;H,5.36;N,11.76;
Found:C,73.84;H,5.45;N,11.63%.
Example 43 Trans -~-phenethyl-5-~henyi-5.6.11.11 a-tetrahydro-1 H-imidazo[1 ',5': 1.6]
pyrido~3.4-b]indole-1.3~?11)-dione The same method as employed in the prepardliGI~ of Example 41 but sldllill~
from trans methyl 1,2,3,4-tetrahydro-1-phenyl-9H-pyrido[3,4-b~indole-3-carboxylate and phenethylal";.,e gave after recry~ 1;on from diethyl ether, the title compound as white crystals m.p.: 240-242~C.
Analysis for C27H23N302:
Calcl.l~tecl C,76.94;H,5.50;N,9.97;
Found:C,77.20;H,5.65;N,10.05%.
F~rnple 44 Tr~ns-5-phenyl-~-(?-pyridylmethyl)-5.6.11.11 a-tetrahydro-1 H-imid;~7n [1'.5':1.6~nyridQ[3.4-b]indole-1.3~1 I)-dione The same method as employed in the prt~ lion of Example 41 but starting from trans methyl 1,2,3,4-tetrahydro-1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylate and 2-(dllli,,o~ tl,yl) pyridine, gave after recrystallisation from methanol, the title co",pound as white crystals m.p.: 165-175~C.
Analysis for C25H20N402:
Calculated: C,73.51;H,4.94;N,13.72;
Found:C,73.46;H5.29;N,13.84%.
Fxample 45 Trans-5-phenyl-2-(4-pyridylmethyl)-5.6.11.11 a-tetrahydro-1 H-imidazo [1 ',5': 1,6]pyrido~3.4-b]indole-1.3(2H)-dione The same method as employed in the preparation of Example 41 but starting from trans methyl 1,2,3,4-tetrahydro-1-phenyl-9H-pyridol3,4-b]indole-3-carboxylate and 4-(aminomethyl) pyridine, gave after recrystallisation from methanol, the title compound as white crystals m.p.: 247-249~C.
Analysis for C25H20N402:
Calculated: C,73.51 ;H,4.94;N,13.72;
Found:C,73.41;H,4.98;N,13.62%.
Example 46 W 096/32003 PCTnEP96/03023 Trans-5-(4-methoxyphenyl)-?-(3-pyridylmethyl)-5.6.1 1.1 1 a-tetrahydro-1 H-imid~7n~1'.5':1.6]~rido[3.4-b]indole-1.3~?1 I)-dione The same m~ll.od as employed in the ~r~pardliGn of Example 41 but sta,li"g from l~ter")ediate 4 and 3-(amir,ometl"~l) pyridine, gave after recryst~lli;;~lio"
from ~U,al~ol, the title a;l"pound as white crystals m.p.: 160-165~C.
Analysis for C26H22N403:
C~lc~ te~: C,71.22;H,5.06;N,12.78;
Found:C,71 .12;H,5.15;N,12.59%.
Example 47 Trans-~-(?~imethylamino-ethyl)-~-(4-methoxyphenyl)-5 .6 . 11 . 1 1 a-tetrahydro-1H-il"id,~1'.5':1.61nyrido ~3.4-blindole-1.3(~1 I)-dione The same method as employed in the pr~pa-dlion of Example 41 but starting from ll~ler",e~lidle 4 and N,N-dilll~ll.yl-ethane-1,2-diamine, gave after recrystallisation frc)m ethanol/water, the title compound as pale yellow crystals m.p.: 1 20-1 24~C.
Analysis for C24H26N403:
C~lcul~ted: C,68.88;H,6.26;N,13.39;
Found:C,68.91 ;H,6.43.N,1 3.23%.
~mple 48 Trans-2-(3~1i" I~ :lh~ylamino-propyl)-5-(4-methoxyphenyl)- 5.6.1 1 .1 1 a-tetrahydro 1H-imid~1'.5':1.6] pyrido [3.4-b]indole-1.3(~H)-dione The same l),etl~od as employed in the pr~ rdlioil of Example 41 but starting from l"ter",ediale 4 and N,N-dimethyl-propane-1,3-diamine, gave after recrystallisation from ethyl acetate/hexane, the title compound as white crystals m.p.: 159-161~C.
Analysis for C25H:28N403:
Calclll~te~: C,69.42;H,6.53;N,12.95;
Found:C,68.89;H,6.60;N,12.91 %.
Example 49 Trans-~-(2-l "o, ~holin-4-yl-ethyl)-5-phenyl-5.6. 1 1.11 a-tetrahydro-1 H-imidazo[1'.5':1,6] pyrido ~3.4-b]indote-1.3(2H)-dione The same method as employed in the preparation of Example 41 but starting from trans methyl 1,2,3,4-tetrahydro-1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylate and 2-morpholin-4-yl-ethylamine, gave after recrystallisation from ethanol, the title compound as white crystals m.p.: 1 83-1 85~C.
Analysis for C25H26N403:
Calclllated: C,69.75;H,6.09;N,13.01;
Found:C,69.68;H,6.17;N,12.80%.
Example ~0 CA 022267~9 1998-01-13 Trans-5-(4-methoxyphenyl)-2-[3-(4-methyl-piperazin-1 -yl)-propyl]- 5.6.1 1.11 a-tetrahydro-1H-imidazo[1',5':1.61 pyrido [3.4-~]indole-1.3(2H)-dione The same ",ell,ocl as employed in the ,t~r~aldliGn of Exa~ le 41 but starting from Intermediate 4 and 3-(4-methyl-piperazin-1-yl)-propylamine, gave after 5 recrystallisation from ethanol/water, the title co"-pound as white crystals m.p.:
1 64-1 68~C.
Analysis for C28H33N503 (0.5 H20):
CalclJl~ted: C,67.72;H,6.9;N,14.1;
Found:C,67.85;H,6.75;N,14.1 3 %.
F~ample 51 Trans-5-(4-metho~yphenyl)-7-(7-pyrrolidin-1 -yl-ethyl)-5.6. 1 1 .1 1 a-tetrahydro-1 H-imi~i~7n[1',5':1.6] ~yrido [3.4-b~;.,rl~1O-1.3~71 I)-dione The same n~ell,od as employed in the pr~pdr~lion of Example 41 but starting 15 from Inle""edidle 4 and 2-pyrrolidin-1-yl-ethyldn.;..e, gave after recry:it~ll;s~lion from ethanol/water, the title compound as white crystals m.p.: 126-130~C.
Analysis for C26H28N403:
Calculated: C,70.25;H,6.35;N,12.60;
Found:C,69.99;H,6.35;N, 1 2.50%.
F~(ample 52 Trans-5-(4-metho~yphenyl)-7-U-(1 -methyl-1~yrrolidin-2-yl)-ethyl]-5.6. 1 1.1 1 a-tetrahydro-1H-i",7cld~o[1'.5':1.6] pyrido ~3.4-b]indole-1.3~2H)-dione The same method as employed in the ~ur~pardliG,, of Example 41 but starting 25 from Intermediate 4 and 2-(1-methyl-pyrrolidin-2-yl)-ethylamine, gave after recrys~ s~tion from l"ell,~"ol, the title colo~uound as white crystals m.p.: 170-1 80~C.
Analysis for C27H30N403:
(',~lcul~ted: C,70.72;H,6.59;N,12.22;
Found:C,70.86;H,6.62;N,12.41%.
Example 53 Trans-5-(4-methoxyphenyl)-5.6.11.1 1a-tetrahydro-1 H-imidazo[1'.5':1.63 pyrido [3.4-b]indole-1.3 (2H)-dione A mixture of Intermediate 4 (0.5 g, 1.48 mmol) and urea (0.1 g) was heated at 220~C for a few minutes. The reaction was then cooled to room temperature and the solid suspended in methanol, filtered then recrystallised from hot methanol to give the title compound as off-white crystals m.p.: 295-305~C.
Analysis for C20H17N303:
Calculated: C,69.15;H,4.93;N,12.10;
Found:C,68.87;H,4.95;N,12.00%.
Example 54 Cis-5-(4-methoxyF~henyl)-5.6.11.1 1a-tetrahydro-1 H-imili~7n~1'.5':1.6] pyrido [3.4-b3indole-1.3 ~1 I)-dione The same method as employed in the prepa,dLion of Example 53 but ~lal lil lg from l,.le".,edidle 3 and urea, gave after rec~lP~ liGn from methanol, the title coln~ound as pale yellow crystals m.p.: 300-310~C.
Analysis for C20H17N303:
Calculated: C,69.115;H,4.93;N,12.10;
Found:C,68.90;H,4.91 ;N,11 .98%.

TABI FTS FOR O~l ADMINISTRATION

A. I:)irect ComlpressiGI) 1. mgltablet Active inyledie.ll 50.0 Crospovidone USNF 8.0 Magnesium Steard~e Ph Eur 1.0 Anhydrous I ~ctose 141.0 The active inyr~3die,lt was sieved and blended with the excipients. The resultant mix was co" "~r~ssed into tablets.

2. mg/tablet Active ingredient 50.0 COIIQj~l Silicon Dioxide 0.5 Crospovidlone 8.0 Sodium Lauryl Sulphate 1.0 Magnesium Stearate Ph Eur 1.0 Microcrystalline Cellulose USNF 139.5 The active ingredient was sieved and blended with the excipients. The resultant mix was compressed into tablets.

B. WET GRANULATIQN

CA 022267~9 1998-01-13 W 096/32003 PCTnEP96/03023 1. mg/tablet Active i, Igrecliel)t 50.0 Polyvinyl pyrollidone 150.0 Polyethylene glycol 50 0 Polysorbate 80 10.0 Magnesium Stearate Ph Eur 2.5 Croscarrnellose Sodium 25.0 Coll~ l Silicon Dioxidè 2.5 Microcrystalline Cellulose USNF210.0 The polyvinyl pyrollidone polyethylene glycol and polysorbate 80 were dissolved in water. The resultant solution was used to granulate the active ingredient. After drying the granules were screened then extruded at elevated temperatures and pressures. The extrudate was milled and/or screened then was blended with the ",icruc,ystalline cellulose cros~"..ellose sodium colloidal silicon ~I;oxide and magnesium stea-dle.
The resultant mix was compressed into tablets.

2. mgltablet Active ingredient ~o.o Polysorbate 80 3 o Lactose Ph Eur 178.0 Starch BP 45.0 Pregelatinised Maize Starch BP 22.5 Magnesium Stearate BP 1.5 The active ingredient was sieved and blended with the lactose starch and pregelatinised maize starch. The polysorbate 80 was dissolved in purified water. Suitable volumes of the polysorbate 80 solution were added and the powders were granulated. After drying the granules were screened and blended with the magnesium stearate. The granules were then compressed into tablets.

W 096/3ioO3 PCTAEP96/03023 Tablets of other sll~r,yll,s may be F,r~l~drt:-l by altering the ratio of activeingredient to the other excipie. ,l~.

FILM COAT~n TA~I FTS

The afor~mentioned tablet formuldliGns were film coated.

Coaf:ing -S-~sl-c., ~iv............ % w/w Opadry whitet 13.2 Purified water Ph Eur to 100.0*

* The water did not appear in the final product. The maximum theoretical weight 10 of solids applied during coc,ling was 20mg/tablet.

t Opadry white is a proprietary material oblai"able from Colorcon Limited UK
which cGI~lai"s hydroxypropyl methylcellulose titaniurn dioxide and triacetin.

15 The tablets were film coated using the coating suspension in conventional film coali"g eq~;~ ",e"l.

CAPSUI FS

1 . mg/c~rs~le Active ingredient 50.0 Lactose 148.5 Polyvinyl pyrollidone 100.0 Magnesium Stearate 1.5 The active ingredient was sieved and blended with the excipients. The mix was filled into size No. l hard gelatin capsules using suitable equipment.

2. mg/capsule Active ingredient 50.0 Microcrystalline Cellulose 233.5 CA 022267~9 1998-01-13 Sodium Lauryl Sulphate 3.0 Crospovidone 12.0 Magnesium stedrdte 1.5 The active il~yledielll was sieved and blended with the excipients. The mix was filled into size No. 1 hard gelatin capsules using suitable equipment.

5 Other doses may be pre,~ar~:d by altering the ratio of active ingredient to excipient, the fill weight and if necess~"/ changing the cP~rsulQ size.

3, mg/capsule Active ingredient 50 0 Labrafil M1 944CS to 1.0 ml The active i-lyr~di~rll was sieved and blended with the Labrafil. The suspension10 was filled into soft gelatin c~psllles using applupriate equipment.

Inhibitory effect on cGMP-PDF
cGMP-PDE activity of compounds of the present invention was measured using 15 a one-step assay adapted from Wells at al. (Wells, J. N., E3aird, C. E., Wu, Y. J.
and Hardman, J. G., Biochim. Biophys. Acta 384, 430 (1975)). The reaction medium contained 50mM Tris-HCl,pH 7.5, ~mM Mg-acetate, 25011g/ml 5'-Nucleotidase, 1mM EGTA and 0.15~1M 8-[H3~-cGMP. The enzyme used was a human recG",~,i"al~l PDE V (ICOS, Seattle USA).
Compounds of the invention were dissolved in DMSO finally present at 2% in the assay. The incubation time was 30 minutes during which the total substrate conversion did not exceed 30%.

25 The IC50 values for the compounds exd",;"ed were deterrnined from concentration-response curves using typically co"ce"lldlions ranging from 10nM
to 10,uM. Tests against other PDE enzymes using standard methodology also showed that compounds of the invention are highly selective for the cGMP
specific PDE enzyme.

cÇMP level measul~,n~ls 5 Rat aortic sr,looU, muscle cells (RSMC) pre,~n:~ according to Chamley et al. in Cell Tissue Res. 177 503 - 522 (1977) were used between the 10th and 25th ssage at conflu~3nce in 24-well culture dishes. Culture media was aspirated and replaced with PBS (0.5ml) conl.~ ing the compound tested at the appropriate conce~ dlioll. After 30 minutes at 37~C partic~ tes guanylate cyclase was stimulated by ~d~iliGn of ANF (100nM) for 10 minutes. At the end of incub~tion the medium was withdrawn and two extractions were performed by addition of 65~/o ethanol (0.25ml). The hNo ell,dnc'.c extracts were pooled and eva,~,orated until dryness using a Speed-vac system. c-GMP was measured after acetylation by scl.llilldlio" ,uroxi",il~/ immu"oassay 1~ (AMERSHAM). The EC50 values are e~r~:ssed as the dose giving half of the stimulation at saturating conce"l,dlior.s Biological data 20 The cG",pounds accol.ling to the ,~r~ser,l invention were typically found to exhibit an ICso value of less than 500 nM and an EC50 value of less than ~ ~M.
In vitro test data for representative co""~ounds of the invention is given in the following table:

25Table 1. In vifro results Example No. IC50 nM ECso l-M
4 <1 ~ 26 (cis isomer) 7 o 3 1(cis isomer) <10 0 3 32 <10 0.2 The hypotensive effects of compounds according to the invention as identified inTable 2 were studied in conscious spontaneously hypertensive rats (SHRs). The W 0~6/32003 PCTnEP96103023 compounds were acl,~,;"istered orally at a dose of 5 or 10 mg/kg in a mixture of5% DMF and 95% olive oil or i.v. at a dose of 10mg/kg in a mixture of 40%
dimeth~,lro"-,amide, 25% tetraglycol, and 25% 94lcose serum. Blood pressure was measured from a catheter i.lse,l~3d in the carotid artery and recorded for 55 hours after aclm;,.isl,dlio0. The results are expressed as Area Under the Curve (AUC from 0 to 5 hours mmHg.hour) of the fall in blood pressure over time.

Table 2. In vivo results Example No. AUC (mmHg.h) 147 (dosed at 10 mg/kg i.v.) 26 (cis i:,o",er) 117 (dosed at 10 mg/kg i.v.) 1 (cis iso".er) 104 (dosed at 5 mg/kg p.o.) 32 65 (dosed at 5 mg/kg p.o.)

Claims (18)

1. A compound of formula (I) and salts and solvates thereof, in which:
R0 represents hydrogen, halogen or C1-6 alkyl;
R1 is selected from the group consisting of:
(a) hydrogen;
(b) C1-6alkyl optionally substituted by one or more substituents selected from phenyl, halogen, -CO2Ra and -NRaRb;
(c) C3-6cycloalkyl;
(d) phenyl; and (e) a 5- or 6-membered heterocyclic ring containing at least one heteroatom selected from oxygen, nitrogen and sulphur, and being optionally substituted by one or more C1-6alkyl, and optionally linked to the nitrogen atom to which R1 is attached via C1-6alkyl;
R2 is selected from the group consisting of:
(f) C3-6cycloalkyl;
(g) phenyl optionally substituted by one or more substituents selected from -ORa, -NRaRb, halogen, hydroxy, trifluoromethyl, cyano and nitro;
(h) a 5- or 6-membered heterocyclic ring containing at least one heteroatom selected from oxygen, nitrogen and sulphur; and (i) a bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and A is a 5- or 6-membered heterocyclic ring as defined in point (h); and Ra and Rb independently represent hydrogen or C1-6alkyl.
2. A compound according to Claim 1 wherein R0 is selected from hydrogen, methyl, bromine and fluorine.
3. A compound according to Claim 1 or 2 wherein R1 is selected from methyl, ethyl optionally substituted by one or more chlorine atoms, butyl, cyclohexyl and benzyl.
4. A compound according to Claim 1 or 2 wherein R1 is selected from hydrogen, cycloalkyl, C1-6alkyl substituted by an -NRaRb substituent, phenyl optionally linked to the nitrogen atom to which R1 is attached via a C1-6alkyl chain, and C1-6alkyl, substituted by -CO2Ra.
5. A compound according to Claim 1 or 2 wherein R1 is selected from pyridyl, morpholinyl, piperazinyl, pyrrolidinyl and piperidinyl, such rings being linked to the nitrogen atom to which R1 is attached via a C1-6alkyl chain.
6. A compound according to Claim 5 wherein the heterocyclic ring is linked to the nitrogen atom to which R1 is attached via a C1-4alkyl chain.
7. A compound according to any of Claims 1 to 6 wherein R2 represents
8. A compound according to any of Claims 1 to 6 wherein R2 represents thienyl, pyridyl, furyl or phenyl, wherein phenyl may be substituted by one or more substituents selected from -ORa, -NRaRb, halogen, hydroxy, trifluoromethyl, cyano and nitro.
9. A compound according to any of Claims 1 to 6 wherein R2 represents a C3-6cycloalkyl group.
10. A compound selected from:
Cis-2-benzyl-5-(3,4-methylenedioxyphenyl)-5,6, 11,11a-tetrahydro-1H-imidazo [1',5':1 ,6]pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-benzyl-5-(3,4-methylenedioxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo [1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-5-(4-methoxyphenyl)-2-methyl-5,6, 11, 11a-tetrahydro-1H-imidazo [1',5':1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-ethyl-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-ethyl-5-(4-methoxyphenyl)-5,6 ,11,11a-tetrahydro-1H-imidazo[1',5':1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-ethyl-5-(3,4-methylenedioxyphenyl)-5,6, 11,11a-tetrahydro-1H-imidazo [1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-ethyl-5-(2-thienyl)-5,6, 11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-5-(4-dimethylaminophenyl)-2-ethyl-5,6, 11,11a-tetrahydro-1H-imidazo [1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-9-methyl-5-phenyl-5,6, 11,11a-tetrahydro-1H-imidazo[1',5': 1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-9-bromo-2-butyl-5-phenyl-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-butyl-5-(4-methoxyphenyl)-5,6, 11, 11a-tetrahydro-1H-imidazo [1',5': 1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo [1',5':1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-butyl-9-fluoro-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo [1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-9-fluoro-5-(4-methoxyphenyl)-5,6, 11,11a-tetrahydro-1H-imidazo [1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(3,4-methylenedioxyphenyl)-5,6, 11,11a-tetrahydro-1H-imidazo [1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-butyl-5-(3-chlorophenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(3-chlorophenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]
pyrido [3,4-b]indole-1,3(2H)-dione;

Cis-2-butyl-5-(4-chlorophenyl)-5,6, 11,11a-tetrahydro-1H-imidazo [1',5':1,6]
pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(4-chlorophenyl)-5,6, 11,11a-tetrahydro-1H-imidazo [1',5':1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(4-fluorophenyl)-5,6, 11, 11a-tetrahydro-1H-imidazo[1',5': 1,6]
pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(4-hydroxyphenyl)-5,6, 11,11a-tetrahydro-1H-imidazo[1',5': 1,6]
pyrido [3,4-b]indole-1,3(2H)-dione;
Cis-2-butyl-5-(4-trifluoromethylphenyl)-5,6, 11,11a-tetrahydro-1H-imidazo [1',5':1,6]pyrido[3,4-blindole-1,3(2H)-dione;
Cis-2-butyl-5-(4-cyanophenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(4-cyanophenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-butyl-5-(4-nitrophenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(4-nitrophenyl)-5,6, 11,11a-tetrahydro-1H-imidazo[1',5': 1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-butyl-5-(3-pyridyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido [3,4-b]
indole-1,3(2H)-dione;
Cis-2-butyl-5-(3-thienyl)-5,6, 11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(3-thienyl)-5,6, 11,11a-tetrahydro-1H-imidazo[1',5':1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-butyl-5-(3-furyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(3-furyl)-5,6, 11,11a-tetrahydro-1H-imidazo[1',5': 1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-cyclohexyl-5-(4-methoxyphenyl)-5,6, 11,11a-tetrahydro-1H-imidazo [1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-cyclohexyl-5-(4-methoxyphenyl)-5,6, 11,11a-tetrahydro-1H-imidazo [1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-cyclohexyl-9-fluoro-5-(4-methoxyphenyl)-5,6, 11,11a-tetrahydro-1H-imidazo[1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;

Trans-2-cyclohexyl-9-fluoro-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-benzyl-5-phenyl-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido [3,4-b]indole-1,3(2H)-dione;
Cis-2-benzyl-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]
pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-benzyl-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]
pyrido [3,4-b]indole-1,3(2H)-dione;
(5R,11aR)-2-benzyl-5-(3,4-methylenedioxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo [1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-benzyl-5-(4-hydroxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo [1',5': 1,6]pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-(2-chloroethyl)-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo [1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-benzyl-5-cyclohexyl-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-benzyl-5-cyclohexyl-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-phenyl-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-cyclohexyl-5-phenyl-5,6,11,11a-tetrahydro-1H-imidazo[1',5': 1,6] pyrido [3,4-b]indole-1,3(2H)-dione;
Cis-2-cyclohexyl-5-phenyl-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6] pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-ethoxycarbonylmethyl-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6] pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-5-(4-methoxyphenyl)-2-[2-(2-pyridyl)-ethyl]-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-cyclopropyl-5-phenyl-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]
pyrido[3,4-b]indole-1,3(2H)-dione ;
Trans-2-phenethyl-5-phenyl-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-5-phenyl-2-(2-pyridylmethyl)-5,6,11,11a-tetrahydro-1H-imidazo [1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;

Trans-5-phenyl-2-(4-pyridylmethyl)-5,6,11,11a-tetrahydro-1H-imidazo [1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-5-(4-methoxyphenyl)-2-(3-pyridylmethyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-(2-dimethylamino-ethyl)-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-(3-dimethylamino-propyl)-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6] pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-2-(2-morpholin-4-yl-ethyl)-5-phenyl-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6] pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-5-(4-methoxyphenyl)-2-[3-(4-methyl-piperazin-1-yl)-propyl]-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6] pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-5-(4-methoxyphenyl)-2-(2-pyrrolidin-1-yl-ethyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6] pyrido [3,4-b]indole-1,3(2H)-dion;
Trans-5-(4-methoxyphenyl)-2-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-5,6,11,11a-tetrahydro -1H-imidazo[1',5':1,6] pyrido [3,4-b]indole-1,3(2H)-dione;
Trans-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6] pyrido [3,4-b]indole-1,3 (2H)-dione;
Cis-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6] pyrido [3,4-b]indole-1,3 (2H)-dione;
and pharmaceutically acceptable salts and solvates thereof.
11. (5R,11aR)-2-benzyl-5-(3,4-methylenedioxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo [1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-cyclohexyl-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo [1',5':1,6] pyrido[3,4-b]indole-1,3(2H)-dione;
Trans-2-butyl-5-(4-methoxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo [1',5':1,6]
pyrido[3,4-b]indole-1,3(2H)-dione;
Cis-2-benzyl-5-(3,4-methylenedioxyphenyl)-5,6,11,11a-tetrahydro-1H-imidazo [1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione;
and pharmaceutically acceptable salts and solvates thereof.
12. A compound according to any of Claims 1-11 for use in therapy.
13. A compound according to any of Claims 1-11 for use in the treatment of conditions where inhibition of cGMP specific PDE is of therapeutic benefit.
14. Use of a compound according to any of Claims 1-11 for the manufacture of a medicament for the treatment of conditions where inhibition of cGMP specific PDE is of therapeutic benefit.
15. A method of treating conditions where inhibition of cGMP specific PDE is of therapeutic benefit, in a human or non-human animal body, which comprises administering to said body a therapeutically effective amount of a compound according to any of Claims 1-11.
16. A pharmaceutical composition comprising a compound according to any of Claims 1-11, together with a pharmaceutically acceptable diluent or carrier therefor.
17. A process of preparing a pharmaceutical composition comprising a compound according to any of Claims 1-11, which process comprises mixing said compound together with a pharmaceutically acceptable diluent or carrier therefor.
18. A process (A) for preparing a compound of formula (I) comprising reacting a compound of formula (II) wherein Alk represents a C1-6alkyl group, with an isocyanate of formula R1-N=C=O, in the presence of a suitable organic solvent, such as a ketone solvent;
or a process (D) which comprises process (A) followed by i) an interconversion step; and/or either ii) salt formation; or iii) solvate, e.g. hydrate, formation.
CA002226759A 1995-07-14 1996-07-11 Tetracycline compounds used as cgmp specific pde inhibitors Abandoned CA2226759A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9514473.9 1995-07-14
GBGB9514473.9A GB9514473D0 (en) 1995-07-14 1995-07-14 Chemical compounds

Publications (1)

Publication Number Publication Date
CA2226759A1 true CA2226759A1 (en) 1996-10-17

Family

ID=10777704

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002226759A Abandoned CA2226759A1 (en) 1995-07-14 1996-07-11 Tetracycline compounds used as cgmp specific pde inhibitors

Country Status (13)

Country Link
US (3) US6001847A (en)
EP (1) EP0859778B1 (en)
JP (1) JP4012246B2 (en)
CN (1) CN1095841C (en)
AT (1) ATE211139T1 (en)
AU (1) AU702548B2 (en)
BR (1) BR9609503A (en)
CA (1) CA2226759A1 (en)
DE (1) DE69618231T2 (en)
ES (1) ES2170252T3 (en)
GB (1) GB9514473D0 (en)
MX (1) MX9800415A (en)
WO (1) WO1996032003A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69833254T2 (en) 1997-06-23 2006-11-02 Cellegy Pharmaceuticals, Inc., Brisbane MICRODOSIS THERAPY OF VASCULAR EXPOSURE BY NO-DONORS
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
EP1114048A1 (en) * 1998-09-16 2001-07-11 Agnès Bombrun Carboline derivatives as cgmp phosphodiesterase inhibitors
MXPA00003997A (en) 1999-04-30 2002-03-08 Lilly Icos Llc Articles of manufacture.
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
CA2407031A1 (en) 2000-04-19 2001-10-25 Lilly Icos Llc Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
JP2004501920A (en) * 2000-06-23 2004-01-22 リリー　アイコス　リミテッド　ライアビリティ　カンパニー Cyclic GMP-specific phosphodiesterase inhibitor
AU2002213419A1 (en) 2000-10-02 2002-04-15 Lilly Icos Llc Condensed pyridoindole derivatives
EP1335923B1 (en) 2000-10-03 2006-07-12 Lilly Icos LLC Condensed pyridoindole derivatives
EP1366760B1 (en) * 2001-02-15 2010-06-30 Mitsubishi Tanabe Pharma Corporation Tablets quickly disintegrated in oral cavity
DE10118306A1 (en) 2001-04-12 2002-10-17 Bayer Ag Composition for intranasal administration of imidazo-triazinone derivative cGMP PDE inhibitor for treatment of erectile dysfunction, also containing local anesthetic to prevent nasal blockage and improve absorption
WO2002088123A1 (en) * 2001-04-25 2002-11-07 Lilly Icos Llc Chemical compounds
MXPA03011081A (en) 2001-06-05 2004-07-08 Lilly Icos Llc Carboline derivatives as pde-5 inhibitors.
ATE455758T1 (en) 2001-12-20 2010-02-15 Merck Serono Sa PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
ES2211295B1 (en) * 2002-07-19 2005-12-01 Consejo Sup. De Investig. Cientificas TETRAHYDRO-BETA-PHENOLIC CARBOLINS AS ANTIOXIDANTS.
AU2003256539B2 (en) * 2002-07-31 2010-03-04 Icos Corporation Modified pictet-spengler reaction and products prepared therefrom
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
EP1606261B1 (en) 2003-03-10 2009-11-04 Nycomed GmbH Novel process for the preparation of roflumilast
CA2529307C (en) * 2003-06-13 2013-12-24 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE10348022A1 (en) * 2003-10-15 2005-05-25 Imtm Gmbh New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
KR20120073287A (en) 2004-03-15 2012-07-04 피티씨 테라퓨틱스, 인크. Carboline derivatives useful in the inhibition of angiogenesis
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
MXPA06010542A (en) 2004-03-15 2007-03-28 Ptc Therapeutics Inc Tetra-cyclic carboline derivatives for inhibiting angiogenesis.
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
WO2006018435A1 (en) 2004-08-18 2006-02-23 Altana Pharma Ag Benzothienopyridines for use as inhibitors of eg5 kinesin
JP5383183B2 (en) * 2005-03-16 2014-01-08 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング A tasted dosage form containing roflumilast
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
CN101389628B (en) 2006-02-22 2013-02-27 4Sc股份公司 Indolopyridines as EG5 kinesin modulators
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
FR2912405A1 (en) * 2007-02-08 2008-08-15 Fourtillan Snc DERIVATIVES OF IMIDAZO [1 ', 5': 1,6] PYRIDO [3,4-B] INDOLES AND THEIR USE IN THERAPEUTICS
BRPI0721950A2 (en) * 2007-08-22 2015-09-29 4Sc Ag indolopyridines as inhibitors of kinesin spindle protein
EP2098524A1 (en) * 2008-03-05 2009-09-09 4Sc Ag Process for preparing enantiomerically pure indolopyrinidines
CN102036663A (en) * 2008-03-24 2011-04-27 细胞基因公司 Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
BR112016010221A2 (en) * 2013-11-22 2018-05-02 Pharmakea Inc tetracyclic autotaxin inhibitors.
AU2014352888B2 (en) 2013-11-22 2019-05-09 Sabre Therapeutics Llc Autotaxin inhibitor compounds
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
MX2016014384A (en) 2014-06-23 2017-01-20 Celgene Corp Apremilast for the treatment of a liver disease or a liver function abnormality.
CN116059203A (en) 2015-05-27 2023-05-05 赛博治疗有限责任公司 Autotaxin inhibitors and uses thereof
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GR79603B (en) * 1982-07-24 1984-10-31 Pfizer
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
IT1217190B (en) * 1988-04-22 1990-03-14 Recordati Chem Pharm USEFUL COMPOUNDS FOR THE TREATMENT AND DIAGNOSIS OF HURRY DYSFUNCTIONS
EP0357122A3 (en) * 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
DE3830096A1 (en) * 1988-09-03 1990-03-15 Hoechst Ag PIPERAZINDIONE WITH PSYCHOTROPER EFFECT
FR2649613B1 (en) * 1989-07-11 1991-09-27 Virag Ronald VASO-ACTIVE MEDICINE
JPH0344324A (en) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya Sexual function invigorator
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
DK0459666T3 (en) * 1990-05-31 1994-12-05 Pfizer Medicines for impotence
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
AU703608B2 (en) * 1994-04-22 1999-03-25 Pentech Pharmaceuticals, Inc. Dosage forms and method for ameliorating male erectile dysfunction
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses

Also Published As

Publication number Publication date
EP0859778B1 (en) 2001-12-19
US6218400B1 (en) 2001-04-17
ATE211139T1 (en) 2002-01-15
CN1095841C (en) 2002-12-11
DE69618231D1 (en) 2002-01-31
AU6613896A (en) 1996-10-30
GB9514473D0 (en) 1995-09-13
MX9800415A (en) 1998-04-30
EP0859778A2 (en) 1998-08-26
US6001847A (en) 1999-12-14
AU702548B2 (en) 1999-02-25
ES2170252T3 (en) 2002-08-01
CN1195350A (en) 1998-10-07
DE69618231T2 (en) 2002-08-22
BR9609503A (en) 2000-03-08
WO1996032003A3 (en) 1997-01-03
JPH11509517A (en) 1999-08-24
US6143757A (en) 2000-11-07
WO1996032003A2 (en) 1996-10-17
JP4012246B2 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
CA2226759A1 (en) Tetracycline compounds used as cgmp specific pde inhibitors
US5981527A (en) Cyclic GMP-specific phosphodiesterase inhibitors
AU707055B2 (en) Tetracyclic derivatives, process of preparation and use
US6462047B1 (en) Carboline derivatives as cGMP phosphodiesterase inhibitors
MXPA98000415A (en) Quimi compounds
MXPA98000411A (en) Quimi compounds
JP2004501919A (en) Chemical compound
US6962918B2 (en) Hexahydropyrazino[1&#39;2&#39;;1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction
HU208137B (en) Process for producing condensed diazepinone derivatives and pharmaceutical compositions comprising same

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued